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Vaccine Mediated Immunity To Malaria 
Abstract 
Malaria infects millions of people every year, and despite recent advances in controlling disease spread, it 
remains a global health concern. Decades of research into both naturally acquired and vaccine mediated 
immunity have given a broad range of correlates of protection. RTS,S, the only licensed anti-malarial 
vaccine, has implicated antibodies against the circumsporozoite protein (CSP) as a key correlate. Not to 
be discounted, CD8+ T cells targeting liver-stage (LS) antigens were associated with protection in 
attenuated sporozoite vaccination. Clearly there is no panacea for malarial immunity, and a broad range 
of responses against multiple antigens is crucial. In this work we develop novel synthetic DNA vaccines 
targeting antigens in multiple Plasmodium pre-erythrocytic life cycle stages, and evaluate the immunity 
elicited by each in the context of murine models of malaria. To further evaluate protection mediated by 
Liver stage antigens, we focused on the exported pre-erythrocytic proteins EXP1, PFN, EXP2, ICP, TMP21, 
and UIS3. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. 
Immunized animals developed robust T cell responses including induction of antigen-specific liver-
localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in 
adjuvanted groups and 71%–88% in non-adjuvanted groups were protected from disease following 
Plasmodium yoelii challenge. To further evaluate protection mediated by sporozoite antigens, five 
synDNA vaccines encoding variations of CSP were designed and studied: 3D7, GPI1, ΔGPI, TM, and DD2. 
ΔGPI generated the most robust immunity, and was the most efficacious in an IV sporozoite challenge. 
We then compared the immunity generated by ΔGPI vs synDNA mimics for two leading malaria vaccine 
candidates (RTS,S and R21). They demonstrated similar anti-CSP antibody responses, however ΔGPI 
induced a more focused T cell response. In an infectious mosquito challenge all three of these constructs 
generated potent inhibition of liver stage infection, with ΔGPI appearing to also provide the best sterilizing 
immunity from blood stage parasitemia. Together these studies demonstrated that synDNA vaccines 
encoding malaria immunogens can provide substantial protection from disease, and highlighted the 
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ABSTRACT 
VACCINE MEDIATED IMMUNITY TO MALARIA 
Sophia M. Reeder 
David B. Weiner 
Malaria infects millions of people every year, and despite recent advances in controlling 
disease spread, it remains a global health concern. Decades of research into both naturally 
acquired and vaccine mediated immunity have given a broad range of correlates of protection. 
RTS,S, the only licensed anti-malarial vaccine, has implicated antibodies against the 
circumsporozoite protein (CSP) as a key correlate. Not to be discounted, CD8+ T cells targeting 
liver-stage (LS) antigens were associated with protection in attenuated sporozoite vaccination. 
Clearly there is no panacea for malarial immunity, and a broad range of responses against 
multiple antigens is crucial. In this work we develop novel synthetic DNA vaccines targeting 
antigens in multiple Plasmodium pre-erythrocytic life cycle stages, and evaluate the immunity 
elicited by each in the context of murine models of malaria. To further evaluate protection 
mediated by Liver stage antigens, we focused on the exported pre-erythrocytic proteins EXP1, 
PFN, EXP2, ICP, TMP21, and UIS3. SynDNA antigen cocktails were tested with and without the 
molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses 
including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the 
co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%–88% in non-
adjuvanted groups were protected from disease following Plasmodium yoelii challenge. To further 
evaluate protection mediated by sporozoite antigens, five synDNA vaccines encoding variations 
of CSP were designed and studied: 3D7, GPI1, ΔGPI, TM, and DD2. ΔGPI generated the most 
robust immunity, and was the most efficacious in an IV sporozoite challenge. We then compared 
the immunity generated by ΔGPI vs synDNA mimics for two leading malaria vaccine candidates 
(RTS,S and R21). They demonstrated similar anti-CSP antibody responses, however ΔGPI 
vi 
induced a more focused T cell response. In an infectious mosquito challenge all three of these 
constructs generated potent inhibition of liver stage infection, with ΔGPI appearing to also provide 
the best sterilizing immunity from blood stage parasitemia.  Together these studies demonstrated 
that synDNA vaccines encoding malaria immunogens can provide substantial protection from 
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CHAPTER 1: INTRODUCTION 
1.1: A brief history of malaria 
Malaria has haunted humanity for nearly as long as we have been keeping 
records. References to a malarial illness in ancient Chinese documents as far back as 
2700 BC1. A similar malady is described in clay tablets from Mesopotamia in 2000 BC, in 
Egyptian papyri from 1570 BC, and in Hindu texts from as far back as the 6th century 
BC1,2. Of course, these early and somewhat vague accounts should be viewed with 
some level of skepticism. We find ourselves on more trustworthy ground with the Early 
Greeks (including Homer in 850 BC, Empedocles of Agrigentum in 550 BC, and 
Hippocrates in 400 BC) who were familiar with the distinctive malarial fevers and 
enlarged spleens seen in patients living on swampy, mosquito ridden land1,3.  
For well over 2500 years, it was believed that malarial fevers were caused by 
miasmas rising from swamps. This concept was so pervasive that it is widely believed 
that the term ‘malaria’ comes from the Italian “mal’aria” which translates to ‘bad air’. It 
was not until the discovery of bacteria by Antonie van Leeuwenhoek in 1676, and the 
subsequent development of the germ theory of disease by Louis Pasteur and Robert 
Koch in 1878-79 that the field turned to searching for a microorganism as an explanation 
for malaria. However, it would be many years before the true cause and mechanism of 
infection was uncovered.  
By 1879, in congruence with the discoveries of Pasteur and Koch, the miasma 
theory was falling out of favor. The two prevailing theories which replaced it, both based 
on the assumption a microorganism was the culprit, were whether the microorganisms 
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were transmitted 1) by air and inhalation, or 2) by water and ingestion. It should be noted 
that at this time the field was still searching for a bacterial cause rather than a protozoan 
one, even so far as the discovery and naming of a novel bacterium, Bacillus malariae, 
which was implicated as the causative agent of malaria by noted German scientist 
Theodor Albrecht Edwin Klebs, who had also been the first to observe the bacterial 
agents for typhoid and diphtheria4.  
An unexpected challenger rose to dispute the bacterial hypothesis. The French 
Army officer Charles Louis Alphonse Laveran was posted in Algeria when he began his 
studies on malaria. Having noted that his malarial patients often exhibited strange 
pigmentation in their enlarged spleens, he adopted the strategy of ‘follow the pigment’ 
and began to search for pigment in the blood of his malarial patients. He observed 
several different forms of erythrocytic organisms in the blood, with varying levels of 
pigmentation. Based on his observations he suggested a course of events for the 
development of these organisms, which culminated in the bursting of red blood cells, 
coinciding with the cyclical fevers characteristic of malaria. He further noted that quinine, 
an anti-malarial commonly used by the colonialist European military officers in Africa, 
removed these organisms from the blood. Laveran named this parasitic protozoan 
Oscillaria malariae and presented his findings to the French Academy of Medical 
Sciences in 18805. He was largely scoffed at by the eminent scientists of the day, who 
did not believe he was observing anything more than disintegrating red blood cells. 
Despite this inhospitable reception, Laveran continued with his research and over time 
convinced key members of the field of the verity of his observations6, and was awarded 
with the Nobel Prize for Medicine in 1907, twenty seven years after his initial, derided 
presentation1,7.  
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Laveran’s work demonstrated that the parasitic protozoan was the 
microorganism responsible for malaria, however the mystery of how humans came to be 
infected with the Plasmodium parasites continued. Centuries of circumstantial evidence 
accumulated, and in 1883 the American physician Albert King assembled and published 
the evidence that would come to be known as the mosquito-malaria doctrine8. Patrick 
Manson, who had previously demonstrated the transmission via mosquitoes of another 
parasitic organism, the filarial worms which cause lymphatic filariasis9, counseled his 
student Ronald Ross to search for a mosquito vector for malaria10. While Ross was 
posted in India, he followed Laveran’s dictate to “follow the pigment” and examined 
several thousand mosquitoes from endemic areas. Eventually he observed the formation 
of pigmented bodies (which he named ‘spores’) on the stomach wall of a mosquito which 
had been experimentally fed on an infected patient. Further, he noted that after feeding 
on an infectious patient, the far more common ‘grey’ culicine mosquitoes never 
contained pigmented bodies, whereas the ’dapple-winged’ anopheline mosquitoes 
contained pigmented bodies which ruptured releasing ‘rods’ which invaded mosquito 
salivary glands11. This was a crucial breakthrough demonstrating the presence of human 
malaria parasites in mosquitoes12.  
It had previously been hypothesized by William MacCallum that Plasmodium has 
a sexual stage of development, after he observed the combination of male and female 
gametes to form a zygote in the blood of crows infected with Haemoproeus columbae, a 
hematozoan closely related to malaria parasites13. Knowing of MacCallum’s work in 
birds, combined with his own work, Ross concluded that Anopheles mosquitoes fed on 
infected mammals, took up the male and female gametocytes of the Plasmodium 
parasite in their blood meal, which then fertilized within the mosquitoes gut, and 
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developed into the ‘spores’ which he had observed, within which rod-like structures were 
produced, which invaded the mosquitoes salivary gland and were subsequently injected 
into a new mammalian host when the infected mosquito fed11. Further evidence 
implicating mosquitoes as the vector for malaria transmission came from a seminal study 
by Italian malariologist Giovanni Battista Grassi. Grassi sent volunteers to the Capaccio 
plains, a malarious region in Italy, and protected a fraction of them from mosquito bites 
from dawn to dusk. Of the 112 volunteers who were protected from mosquito bites, only 
5 developed malaria. In contrast, all 415 of the unprotected volunteers contracted the 
disease14. Not only did this study cement the role of mosquitoes as the vector for 
Plasmodium scientifically, but it also set the precedent for controlling malaria by reducing 
contact with infected mosquitoes, through methods such as screening and mosquito-
proofing homes which are still commonly employed today.  
Scientists now understood that malaria was caused by a species of the parasitic 
protozoa Plasmodium, that it infected red blood cells, had a sexual stage of development 
in the blood, and was transmitted by mosquitoes. However, the understanding of the 
lifecycle of malaria in humans remained incomplete until the 1930s. The parasites could 
not be observed in the blood during the first ~10 days after infection, and it was unknown 
where in the body the parasites developed. Grassi and colleagues had begun to 
investigate the possibility of development in other cells types, but these endeavors were 
abandoned following a study by well-respected German scientist Fritz Schaudinn in 
1903 which mistakenly described the direct invasion of red blood cells by the infective 
sporozoites of Plasmodium vivax15. Despite the field’s inability to confirm these 
observations, Schaudinn’s hypothesis dominated scientific opinion for over forty years, 
and is now referred to as Schaudinn’s fallacy. The question of exoerythrocytic parasite 
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development was first properly addressed in avian rather than mammalian malaria16. 
MacCallum, a noted avian malariologist who had also been the first to postulate a sexual 
stage of development for Plasmodium, observed developmental phases of Plasmodium 
relictum in the livers and spleens of infected birds13. However it was not until 1937 that 
Sydney James and Parr Tate conclusively demonstrated that in Plasmodium 
gallinaceum infections in chickens there was a phase of multiplication between the 
injection of sporozoites, and the appearance of parasites in the blood, and that this 
occurred in cells of the reticuloendothelial system17. There was a delay of another ten 
years until the same conclusion could be reached in primate Plasmodium infections; in 
1947 Henry Shortt and Cyril Garnham showed that a phase of division in the liver 
preceded the development of parasites in the blood18–20. Shortly after, Shortt, Garnham, 
and colleagues found exoerythrocytic forms of Plasmodium vivax21, Plasmodium 
falciparum22, and Plasmodium ovale23 in human volunteers. The only remaining mystery 
in the life cycle of Plasmodium parasites was the source of the long pre-patent periods 
and the appearance and reappearance of parasites in blood seen in some strains of 
Plasmodium vivax. This question was answered by Wojciech Krotoski in 1982 while he 
was working with Garnham’s team, and discovered the dormant hypnozoite stage of 
Plasmodium vivax24.  
After thousands of years of living with malaria, an unknown French scientist with 
a rudimentary microscope noticed organisms in his malaria patient samples, and 122 
years later the complete genome for Plasmodium falciparum was published in 200225,26. 
There remain many questions to be answered concerning the basic biology of 
Plasmodium, and malaria remains an immense global health burden. New technologies 
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will allow us to address these questions in innovative and integrative ways as we move 
forward into the future from the history of malaria.  
1.2: The basic biology of malaria parasites 
Malaria continues to cause disease in 229 million humans annually with a death 
toll of approximately 409,000 per year27. Malaria infections are caused by the plasmodial 
species of parasite; six species of Plasmodium are infectious to humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi, 
Plasmodium ovale wallikeri, and Plasmodium knowlesi. Plasmodium falciparum is 
responsible for the majority of deaths caused by malaria, and thus is often considered 
the most important for human health. Although the focus on Plasmodium falciparum is 
certainly appropriate, Plasmodium vivax should not be discounted, as it has recently 
been shown to be a comparable cause of severe disease in Southeast Asia, and it has 
been increasingly argued that Plasmodium vivax is underestimated28. Plasmodium 
malariae, Plasmodium ovale curtisi, and Plasmodium ovale wallikeri are much less 
common causes of severe disease29. Plasmodium knowlesi was previously considered 
to be a primate-infecting parasite, however it is now known that Plasmodium knowlesi is 
a zoonosis involving macaque and leaf monkeys as reservoir hosts with Anopheles 
mosquitos as the vectors, in Malaysia and elsewhere in Southeast Asia30,31. Further, 
advances in PCR identification have revealed that many infections previously attributed 
to Plasmodium malariae were in fact caused by Plasmodium knowlesi31.  
Like many other apicomplexan parasites, Plasmodium parasites have a complex 
life cycle, with stages in both vertebrate and invertebrate hosts (Figure 1.1). As Ronald 
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Ross concluded many years ago, Plasmodium sporozoites are injected into the dermis 
during a blood meal by a female Anopheles mosquito12. The sporozoites then use gliding 
motility to reach and penetrate a blood vessel, allowing them to enter the blood stream32. 
Many sporozoites are destroyed in the skin and drained to the lymphatics29. Those that 
successfully exit the dermis and access the blood stream quickly access the liver via 
traversal. The sporozoites cross the sinusoidal barrier comprising endothelial cells and 
macrophage-like kupffer cells33, their traversal of these cells is mediated by the 
formation of a transient vacuole34. When sporozoites are injected into the dermis they 
are in ‘migratory mode’ and upon interaction with hepatocytes convert to ‘invasive 
mode’. One molecular signal for this transition is sporozoite recognition of hepatocytes 
through binding highly sulfated proteoglycans, activating calcium dependent protein 
kinase 6 (CPK6)35, which in turn activates the processing of the circumsporozoite 
surface protein (CSP) which coats the surface of the parasite and is crucial for invasion36 
(see chapter 3 for CSP specific background).  
Once the sporozoite has successfully invaded the hepatocyte, the sporozoite 
transforms to a liver stage or exo-erythrocytic form (EEF). The liver stage (LS) parasite 
is separated from the infected hepatocyte by a selective parasitophorous vacuolar 
membrane (PVM) of host hepatocyte plasma membrane origin32,37. The growing LS 
parasite acquires nutrients from its host hepatocyte and at the same time prevents its 
apoptosis38–41. This stage of development culminates in the release of up to 40,000 
merozoites/hepatocyte into the blood stream by budding of parasite filled vesicles called 
merosomes42. See chapter 2 for in-depth liver stage background.  
Free merozoites then invade erythrocytes in a multistep process including 1) 
pre-invasion, 2) active invasion, and 3) echinocytosis, all of which is complete within two 
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minutes43. The pre-invasion step involves receptor-ligand interaction between the 
merozoite and the erythrocyte, which results in parasite actomyosin motor driven 
deformation of the host cell43. Following this, the irreversible attachment of merozoites to 
erythrocytes occurs via formation of a tight junction formed between parasite derived 
proteins: AMA1 and the RON complex. The RON complex is deposited in the 
erythrocyte, with RON2 spanning the host membrane and binding to AMA1 on the 
merozoite surface44. Lipid-rich rhoptry contents form the parasitophorous vacuole 
membrane (PVM) as the merozoite is propelled into the erythrocyte using force 
generated by the parasite actomyosin motor45. Finally, after the active invasion phase is 
complete, fusion of membranes at the posterior end of the merozoite seals the parasite 
within the PVM within the erythrocyte. Echinocytosis follows, and causes the erythrocyte 
to shrink and form spiky protrusions43.  
Over the next two days, schizogony results in 16-32 new merozoites, which 
egress when developed, destroying the host erythrocyte in the process as they are 
released to access new host cells for invasion46–48. This explosive release of merozoites 
coupled with the rupture of host erythrocytes are responsible for the characteristic fevers 
and pathophysiology associated with malaria infections. Infected erythrocytes undergo 
extensive modification, which allows the intracellular parasite to grow and hide from host 
immune responses49. During these rounds of schizogony, a number of parasites 
transition to sexual development, to form male and female gametocytes. The 
gametocytes are taken up by a female Anopheles mosquito during a blood meal, receive 
activation signals including change in temperature and pH, and rapidly convert to fertile 
gametes50,51. After fertilization, the zygote further converts into the motile and invasive 
ookinete stage. Once the ookinetes are formed, they exit the gut lumen by traversing 
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through the mosquito midgut epithelial cell layer, before depositing on the basal site of 
the epithelium and converting once more into sessile oocysts, which undergo sporogonic 
replication37. Over the course of the next two weeks, this results in infectious sporozoites 
which migrate to the mosquito salivary glands and are subsequently injected into the 
human dermis during the next blood meal, and the cycle begins anew52,53.  
1.3: Naturally acquired immunity to malaria 
The nature of malaria infections has made the task of identifying correlates of 
protection a difficult one. Many cohort studies have attempted to address this question, 
however small effect sizes and the polymorphic nature of immunogenic parasite 
proteins54, combined with the inherent difficulty of addressing heterogeneity of malaria 
exposure (age, local transmission pressure, maintenance of baseline immune responses 
throughout the study or lack thereof)55 have made the identification of true correlates of 
protection ambiguous at best. Further complicating this search, unlike many pathogens 
which elicit a highly potent, long-lived immune response, human naturally acquired 
immunity to malaria is less potent and is short lived56; true immunity to infection is rare, 
though immunity to disease does develop naturally over time and repeated exposure57. 
This difference between immunity to disease vs immunity to parasites is an important 
consideration. There is huge variability in parasite strains, and immunity is acquired to 
each isolate that is survived, giving ‘strain-specific immunity’. Over time, immunity builds, 
due to the acquisition of a repertoire of responses to many different isolates, and/or the 
development of a cross-protective response to shared antigenic targets29.  
Much of naturally acquired immunity targets the asexual blood stage, and is 
antibody mediated. Blood stage parasitemia is associated with the clinical symptoms of 
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malaria infection, as the cycles of rupturing erythrocytes causes an upregulation of pro-
inflammatory cytokines. Antibodies to blood stage antigens are associated with clinical 
immunity in endemic areas58–60. Antibodies are generated either against the free 
merozoite, or against the infected erythrocyte. Antibodies against the free merozoite 
prior to invasion could block the ability of the parasite to enter the erythrocyte, or lead to 
cell-mediated destruction of the parasite via mechanisms including opsonophagocytosis, 
antibody dependent cellular inhibition (ADCI), or neutrophil mediated killing29. Antibodies 
against the infected erythrocyte may also recognize the highly modified host cell surface, 
triggering cell mediated ingestion or killing, or blocking cyto-adhesion of the infected 
erythrocyte to endothelial cells, making it susceptible to splenic removal61.  
Antibodies against parasite proteins from developmental stages other than the 
asexual blood stage have also been identified as being important. The Glutamate-rich 
protein (GLURP) is expressed in all the developmental stages of Plasmodium falciparum 
in humans62. The presence of antibodies to GLURP is associated with protection from 
clinical disease63,64, and antibody-dependent cellular inhibition is hypothesized to be an 
important element in GLURP-specific protective immunity64. Antibodies against Liver-
stage antigen 1 (LSA-1) are also associated with protection against clinical malaria63. 
LSA-1 is produced shortly after hepatocyte invasion and accumulates within the PVM 
surrounding the mass of developing merozoites65. LSA-1 plays a critical role during late-
stage liver schizogony, and is thus important in the parasite transition from liver to blood 
stages66. Antibodies against the circumsporozoite protein (CSP), a key surface protein of 
the sporozoite stage of the parasite, have long been identified as being of importance for 
protection from clinical malaria (see chapter 3 for further information on CSP).  
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A key caveat when considering our knowledge concerning the naturally acquired 
correlates of protection is the limitations on the types of samples that can be collected 
from human patients. If the immunological information cannot be gleaned from a blood 
sample, either through sera analysis or through analysis of cryo-preserved peripheral 
blood mononuclear cells (PBMCs), it will be difficult to assess in a human population. 
This leaves out tissue resident populations of cells, which vaccine studies have indicated 
are of importance (see below). Though the study of cohorts of patience in endemic areas 
for naturally acquired immunity has been enlightening, many lessons about anti-malarial 
immunity have also been learned from decades of vaccine work.  
1.4: Anti-malaria vaccines- lessons learned 
There are three main avenues that have been explored for anti-malarial 
vaccines. These are 1) pre-erythrocytic vaccines, which aim to prevent malaria by 
stopping infection before it reaches the symptomatic blood stage, 2) asexual blood stage 
vaccines, which will be important for controlling morbidity and mortality, and 3) sexual 
blood stage vaccines, which have the potential to interrupt the transmission cycle, but do 
not have direct effect on an already established infection in the vaccinee.  
The goal of pre-erythrocytic vaccines is to inhibit hepatocyte infections and 
hepatic parasite development, which will in turn limit erythrocyte invasion and 
symptomatic infection. Mechanisms of protection for vaccines targeting these 
developmental stages include antibody responses which prevent sporozoites from 
invading hepatocytes, and cytotoxic T cells which destroy infected liver cells57. By far the 
most notable anti-sporozoite vaccine is RTS,S/AS01. As for anti-liver stage vaccines, 
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attenuated whole sporozoite vaccines take center stage, though alternative vaccines 
including those using a prime and trap strategy have also been making headway.     
RTS,S/AS01 (RTS,S), one of the longest studied candidate vaccines (developed 
by GSK over decades) is focused on generating immunity to CSP, the circumsporozoite 
protein of Plasmodium falciparum (Pf). RTS,S is a recombinant protein-based vaccine 
comprised of a fragment of CSP containing a section of the repeat region, and the T cell 
epitopes of the c-terminus attached to the Hepatitis B surface antigen protein, and 
delivered with additional HbsAg to encourage the formation of virus-like-particles in 
yeast, which are then harvested and administered with an adjuvant to humans to 
generate a T cell and antibody response. This is the only vaccine to show significant 
reduction in malaria in young children living in endemic regions. A phase 3 trial which 
spanned 5 years demonstrated that children aged 5-17 months who received 4 doses of 
RTS,S had a 39% reduction in malaria cases, and a 29% reduction in severe malaria 
cases over 4 years of follow-up67. After positive recommendations by WHO advisory 
boards, three countries, Ghana, Kenya, and Malawi began introducing RTS,S in 201927. 
In the coming years, the Malaria Vaccine Implementation Programme (MVIP) will assess 
the feasibility of administering the recommended 4 doses of the vaccine in children, the 
potential role in reducing childhood death, and the safety of RTS,S in the context of 
routine use68 as well as in specific important subpopulations.  
An important recent advance in pre-erythrocytic malaria vaccines is the 
development of a novel polyvalent immunogen R21, a recent anti-malaria vaccine 
candidate, which builds on the knowledge gained from RTS,S. In contrast to RTS,S, R21 
delivers a higher ratio of CSP to the Hepatitis B surface antigen (HBVsAg), which is in a 
1 to 1 ratio as opposed to the 1 to 4 ratio of RTS,S5.  Thus far R21 has proven to be well 
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tolerated and immunogenic in early trials, as well as protective in a controlled human 
malaria infection study (CHMI)69,70. The correlates of immunity which have emerged from 
these malaria vaccines support the importance of anti-CSP antibodies primarily but also 
suggest a role for T cells for imparting protection from Plasmodium infection67,69–74. The 
role of anti-Plasmodium T cells in vaccination has been highlighted by attenuated 
sporozoite vaccines75.  
The only vaccination method that has led to long lasting complete sterile 
protection against malaria parasite challenges in animals and in controlled human 
malaria infection (CHMI) is immunization with live irradiation-attenuated sporozoites76,77. 
Field studies in Burkina Faso, Mali, Kenya, Gabon, and Tanzania are currently following 
up on this approach78. While these studies are important for the efforts to develop an 
effective malaria vaccine, attenuation by irradiation is not easily standardized for human 
use. Over-irradiated sporozoites confer little protection while under-irradiation provides 
risk for breakthrough infections. More recently, attenuation of sporozoites was conducted 
by targeted deletion of genes that encode LS essential proteins in the mouse model, or 
by delivery of whole-sporozoites concurrently with chemoprophylaxis. In all attenuation 
methods, Plasmodium sporozoites invade hepatocytes within vacuoles, then cease 
growth and do not cause Plasmodium infection of the blood32,37,79,80. The protection 
conferred by attenuated sporozoites was confirmed to be mainly mediated by CD8+ T 
cells targeting LS antigens and not by antigens presented on the surface of migrating 
sporozoites81–85. Recent studies pointed out that when compared to attenuated strains 
that cease their LS development early, attenuated strains that grow longer in 
hepatocytes before ceasing growth led to more significant protective immune 
responses81. This indicated that significant exposure to LS antigens can enhance 
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vaccine effectiveness. Further, liver-associated T cells have been implicated in anti-
malarial immunity following irradiated sporozoite vaccination86–88. When T cells lack 
CXCR6, a cell surface marker highly expressed by liver-infiltrating CD8 T cells, there is a 
reduction of liver-associated89 memory and sporozoite immunity86. It has been 
established that CD8 tissue resident memory T cells are essential for protection against 
LS malaria following vaccination87. Therefore, LS proteins are also important candidates 
for inducing protective CD8+ T cell responses in the attenuated sporozoite model. 
Despite the evident potential of live attenuated parasite models as vaccines, the 
feasibility and large-scale application of live attenuated sporozoites that must be 
produced aseptically in mosquitoes in high amounts is still in development90.  
In contrast to pre-erythrocytic vaccines, the objective for anti-asexual blood stage 
vaccines is to mimic the observed naturally acquired immunity that people living with 
repeated malaria exposure in endemic regions develop. These patients achieve a state 
in which their immune systems control erythrocyte invasion to some extent, resulting in 
fewer disease symptoms or entirely asymptomatic infections91,92. This class of vaccine is 
designed to elicit immune responses that will block/limit merozoite invasion of 
erythrocytes, and prevent rapid replication of merozoites by targeting merozoite surface 
protein (MSP) family members, apical membrane antigen 1  
(AMA-1), and the reticulocyte homolog (Rh) proteins93–96. Alternatively, blood stage 
vaccines may target parasite antigens which are embedded in the infected erythrocyte 
membranes, such as PfEMP197. A common challenge for blood stage antigens, is that 
while they are usually highly immunogenic, they are also highly polymorphic, so elicit 
antigen and strain specific responses93,94. In contrast, antigens such as Rh which are 
highly conserved95,96 tend to be less immunogenic98.  
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The final class of anti-malaria vaccines are anti-sexual blood stage vaccines, 
also known as transmission blocking vaccines, or TBVs. TBVs are designed to interrupt 
the transmission of parasites between humans and the mosquito vector, by exploiting 
host immune responses to parasite proteins, including both pre-fertilization and post-
fertilization antigens. These host immune responses against sexual stage parasites are 
able to reduce the infectivity of the parasite, thus decreasing malaria transmission99,100. 
However, a key caveat for TBVs, which are known as the ‘altruistic vaccine’ is that they 
provide no immunity from disease for the vaccinee. For this reason, TBVs will likely be 
best utilized as a component of a multi-antigen vaccine targeting multiple stages of 
parasite development.  
By themselves, none of the vaccination methods laid out above have been able 
to achieve high-level, durable, cross-strain protection from malaria. In order to pursue 
the goal of malaria elimination, radical new tools must be developed.  
1.5: Advances in Vaccinology and their potential for combatting complex 
pathogens 
Since the work of Edward Jenner in 1796, the field of vaccinology has continually 
evolved. Jenner noticed that inoculation with pus from cowpox lesions conferred 
protection from smallpox infections101, and this landmark discovery paved the way for 
vaccines, eventually resulting in the eradication of smallpox in 1979 following a global 
vaccine administration program102. Jenner’s work was later refined by Louis Pasteur, 
who was the first to attenuate viruses for use as vaccines. Although Jenner is often 
lauded as the founder of vaccinology, it was Pasteur who established the basis of 
vaccinology, i.e., the principle of inoculation, inactivation, and administration of disease-
causing pathogens. Pasteur’s principles allowed for the development of so-called “1st 
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generation” vaccines, based on whole microorganisms which had been killed or 
otherwise attenuated; this family of vaccines includes those against the plague, 
pertussis, and smallpox, and the BCG vaccine for tuberculosis103,104. In the second half 
of the twentieth century, improvements in mammalian cell culture technology enabled 
the development of live attenuated “2nd generation” vaccines such as those for polio, 
measles, rubella, mumps, and varicella. As a result, many of humanity’s greatest 
infectious disease scourges have been greatly reduced, and polio has been nearly 
eradicated105. It is without question that traditionally developed vaccines have changed 
the landscape of public health, having prevented more than 700 million incidences of 
disease and more than 150 million deaths in the past century106. That said, conventional 
methods of vaccine design and development have limitations. First and second 
generation vaccines have been unable to provide protection from pathogens with 
antigenic hypervariability, such as HIV or HCV, or from pathogens with an intracellular 
phase which cause infections that are partially or primarily controlled by T cells, such as 
tuberculosis or malaria107. Antigenic polysaccharides, which primarily produce a B cell 
dependent immune response, are covalently linked to carrier proteins, thereby providing 
helper T cell activation. These glycoconjugate vaccines induced a stronger antibody 
response, and thus increased their protective efficacy. Progress in molecular biology led 
to the further development of this class of vaccines, in which purified recombinant 
protein antigens are made to form a virus-like-particle (VLP)108.  
Decades of research on vaccine candidates for malaria, as well as countless 
studies interrogating the parasite’s basic biology and epidemiology have gleaned 
valuable information. However, leveraging recent advances in bioinformatics, systems 
biology, and non-traditional vaccinology has the potential to transform the field of malaria 
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vaccines. Reverse vaccinology allows teams to have access to the entire repertoire of 
pathogen proteins by sequencing and analysis, which can enable comparisons of 
conserved sequences shared among pathogen strains within the same species109. 
Advances in structural vaccinology have given us an improved understanding of the 
native structures of biological macromolecules, and how changes in their structure affect 
their function. This can in turn assist the identification of suitable epitopes.  
Traditional vaccine design has relied on strategies like protein subunit vaccines 
and weakened or killed versions of the pathogen in question. These techniques, while 
valuable, have not yielded a high-efficacy malaria vaccine with durable cross-strain 
protection. Advances in vaccinology, notably in the vaccine platforms of nucleic acid 
vaccines and nanoparticle vaccines could be a solution. Synthetic nucleic acid vaccines 
combine the advantages and high immunogenicity of in situ expression with the high 
safety of subunit vaccines. Additionally, nucleic acid vaccines do not have potential 
complications from pre-existing vector immunity as in the case of virally vectored 
vaccines. Of key importance for infectious diseases of global health relevance like 
malaria, nucleic-acid vaccines also have the potential to be produced simply and 
inexpensively108. Among nucleic acid vaccines, both RNA and DNA vaccines must be 
discussed. 
RNA vaccines, which are based on mRNA or RNA replicons, have some 
advantages and some disadvantages over DNA. RNA vaccines are active in the 
cytoplasm and do not require delivery to the nucleus, however RNA vaccines are also 
more susceptible to degradation and thus require additional stabilizing technology110. 
mRNA vaccines are enjoying a rise in popularity; while the proof of concept for RNA 
vaccines in humans was achieved in cancer vaccines years ago111–113, the advent of 
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SARS-CoV-2 and the rapid response of Moderna and Pfizer/BioNTech resulting in the 
first FDA approved SARS-CoV-2 vaccines both being mRNA vaccines114,115 will surely 
result in a surge in mRNA vaccines in the years to come.  
DNA vaccines held much of the focus in the nucleic acid vaccine field for many 
years, and have been shown to be potent and efficacious in a wide variety of animal 
species; this work has resulted in several licensed veterinary products116–119.  
 Initial studies of DNA vaccines in humans showed less than impressive 
immunogenicity120, however recent advances in improved delivery through the use of 
electroporation121,  or through coadministration of immunostimulatory cytokines as 
molecular adjuvants are overcoming these limitations122,123. Of note the low initial 
immunogenicity was likely tied to lower levels of DNA expression in the early years of 
DNA vaccine development, however innovative delivery methods such as jet delivery, 
gene gun delivery, nanoparticle delivery, and others have demonstrated increased DNA 
uptake in vivo124. With these innovations has come pre-clinical and clinical success 
stories for DNA vaccines; multiple studies have now reported that synDNA vaccines 
generate robust cellular and humoral immune responses against pathogens, with impact 
in challenge model systems, as well as demonstrating a remarkable safety profile in the 
clinic125–128.  
Adaptive electroporation (EP), a technique which controls the energy delivered 
during in vivo EP, increases the initial uptake pf plasmid by local cells approximately 
500x over classical needle and syringe delivery129 . Following injection, plasmid DNA is 
taken up by local cells at the site of injection, where the DNA is transcribed into mRNA 
and translated into the antigen of interest intracellularly. In addition to the local myocytes 
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which have become antigen factories, locally transfected antigen presenting cells 
(APCs) can directly traffic to the regional lymph node, which is critical to initiating the 
immune response130,131. Translated antigen can also be shed exogenously, and picked 
up by APCs for subsequent cross presentation. Shed exogenous soluble antigen can 
also drain to the regional lymph node, allowing for the engagement of B-cell immunity132. 
Thus, local tissue at the site of injection becomes a sustained source of antigen, allowing 
for presentation of antigen on major histocompatibility complex I (MHC-I) or MHC-II 
molecules for re-expansion of lymph node primed CD8+ or CD4+ cells respectively133. 
DNA vaccines also have potential as part of a heterologous prime-boost routine, 
whereby DNA vaccines can effectively prime B- and T-cell responses (Figure 1.2). 
Heterologous prime-boost vaccine strategies generally use either a viral vector or a DNA 
vaccine for priming, followed by a protein-based vaccine boost134. This immunization 
schedule results in the induction of a strong cellular immune response, as well as a 
higher and more specific antibody response as compared to homologous 
immunization135.  
I hypothesize that DNA vaccines are an ideal vaccine platform for a next-
generation anti-malaria vaccine, due to their ease of production and cost-effectiveness, 
and their ability to induce robust cellular and humoral immunity, which is of key 
importance for a pathogen with both extracellular and intracellular phases.  
1.6: Summary 
While the global incidence of malaria has decreased in the past decade, the 
infection remains a significant global health concern. In 2019 there were approximately 
229 million cases worldwide, of which 93% were in the WHO African Region136. Those 
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cases resulted in 409,000 fatalities, with a high burden in younger populations, as 67% 
of cases occur in children under 5 years of age136. Nearly half of the world’s population is 
at risk for malaria infection27. Malaria is caused by infection by Plasmodium parasites, 
and while six species can cause disease in humans, Plasmodium falciparum (Pf) 
remains the most prevalent malaria parasite, accounting for 99.7% of all cases in the 
WHO African region136. Symptoms can arise 10-15 days after the infective mosquito bite, 
and include fever, headache, and chills, which can progress to severe illness and 
potentially death27.  
The WHO Global Technical Strategy for Malaria 2016-2030 established a 
number of goals to be achieved globally by 2030, including 1) reducing malaria case 
incidence by 90% by 2030, 2) reducing malaria mortality by at least 90%, and 3) 
eliminating malaria in at least 35 countries27. Malaria elimination is defined as the 
interruption of local transmission of a specified malaria parasite species in a defined 
geographical area as a result of deliberate actions27. Achieving these goals will require 
varied approaches, including vector control approaches such as insecticide treated bed 
nets and indoor spraying with residual pesticides. The inclusion of a vaccine into these 
techniques has always been of paramount importance, and this importance continues to 
grow as drug resistant strains of the parasite emerge27. The following chapters describe 
the development of and immune mechanisms behind multiple synthetic DNA vaccines 
targeting pre-erythrocytic stages of malaria infection. Understanding malaria infection, 
the immune response elicited by vaccination, and the continued development of novel 
vaccine strategies remain crucial elements in the world-wide battle against malaria.  
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Figure 1.1: Plasmodium Life Cycle. Figure generated with BioRender© 
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CHAPTER 2: The importance of liver localized T cells in 
protection from malaria 
Parts of this chapter were previously published in Vaccines: 
Reeder, S. M., Reuschel, E. L., Bah, M. A., Yun, K., Tursi, N. J., Kim, K. Y., ... & 
Perrin, B. (2020,January). Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive 
Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a 
Mouse Model. Vaccines, 8(1), 21. 
Introduction 
As summarized above, infection in humans begins when the human is bitten by 
an infected female Anopheles mosquito and inoculated with sporozoites, which then 
travel through the blood or lymphatics, and invade hepatocytes. This chapter will focus 
on the development of a pre-erythrocytic vaccine targeting liver stage antigens, and the 
potential mechanisms of protection for the immunity it drives.  
I hypothesize that LS proteins delivered by a synthetic optimized DNA plasmid 
vaccine should induce protective immunity similar to that observed with live attenuated 
parasite models (See Chapter 1.4). While there are a plethora of liver stage antigens, I 
focused on the following antigens, which are expressed across Plasmodium spp.: EXP1, 
profilin (PFN), EXP2, ICP, TMP21, and UIS3. EXP1 (exported protein 1) is a glutathione 
transferase, located at the parasite-host interface, which efficiently degrades cytotoxic 
hematin, and is associated with the metabolism of and susceptibility to artesunate, a 
frontline anti-malarial drug137,138. EXP1 has been previously shown to be immunogenic in 
a mouse model of malaria139. There is evidence in humans that EXP1 may be an 
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important anti-malarial target, as a positive antibody response to EXP1 correlated with a 
statistically significant decrease in malarial infection in children in Burkina Faso140. 
Profilin (PFN) has been detected in all life cycle stages, including sporozoites and 
merozoites, and abundant PFN expression suggests PFN is important for Plasmodium 
life cycle progression141,142. Like all apicomplexans, Plasmodium utilizes a highly 
specialized microfilament system for motility and host cell invasion, and profilin plays a 
key role as an actin-sequestering protein143,144. It has been shown that disturbing 
expression of PFN results in complete life cycle arrest145. Similarly to EXP1, exported 
protein 2 (EXP2) is an integral vacuolar protein146. EXP2 resides primarily on the 
vacuolar face of the PVM, and likely constitutes the membrane pore147. In Plasmodium, 
inhibitor of cysteine proteases (ICP) has been shown to be necessary for malaria 
transmission from mosquitos to mammals, sporozoite motility,  erythrocyte invasion148, 
and liver stage development149. While little is known about transmembrane protein 21 
(TMP21), vaccination with TMP21 reduced liver stage parasite load in a mouse model 
and has been shown to contribute to the protective immunity elicited by whole parasite 
vaccinations150. The antigen UIS3 (upregulated in infective sporozoites-3) is a 
membrane protein that is localized to the PVM in infected hepatocytes151 and interacts 
directly with host liver-fatty acid binding protein (L-FABP)152. UIS3 is essential for early 
liver stage development153 and vaccination with a ChAd63-MAV vaccine containing UIS3 
has been shown to be partially protective in a mouse model154.  
One of the strengths of the synthetic DNA vaccine platform is the ease with 
which antigens can be co-formulated with each other and with molecular adjuvants in the 
clinic155–158. Given the focus on induction of cellular immunity, we explored using 
synthetic DNA-encoded plasmid IL-33 (pIL-33) as a molecular adjuvant. pIL-33 is a 
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member of the IL-1 family, which although originally associated with Th2 immunity, has 
been shown to facilitate the generation of protective Th1 and CD8 T cell immunity156. 
pIL-33 has immunoadjuvant effects in an HPV-associated model for cancer 
immunotherapy in which cell-mediated immunity is critical for protection and has been 
shown to enhance potent antigen specific effector and memory T-cell immunity in a DNA 
vaccine setting158. The ability to induce potent cell mediated immunity is important for a 
vaccine against LS malaria, as is the fact that IL-33 is predominantly expressed at the 
epithelial barrier as the first line of defense against pathogenic threats, activating a 
variety of immune cells159, which may be relevant to the necessity for Plasmodium 
sporozoites to transverse through the dermis before LS infection. Consequently, IL-33 
was chosen as a molecular adjuvant for this study. Another strength of the DNA vaccine 
platform is its ability to drive functional, localized cell mediated immunity (CMI). Prior 
work studying the immunity from a hepatitis B DNA vaccine showed the ability of this 
platform to drive vaccine specific CTLs to traffic to the liver, an organ that is known to be 
tolerogenic and suppress T cell responses160. The ability of this platform to drive vaccine 
specific CTLs in this location highlights the potential to drive relevant, functional CMI in 
the context of a liver infection. 
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Results 
synDNA vaccine construct design and in vitro expression. 
Previously identified LS proteins were optimized and encoded into a modified pVax 
plasmid. Plasmid 1 contains an IgE leader sequence, the EXP1 gene sequence, a linker 
sequence, and the PFN gene sequence. Plasmids 2, 3, 4, and 5 each contain an IgE 
leader sequence, the gene sequence for EXP2, ICP, TMP21, or UIS3 respectively, and 
an HA tag (Figure 2.1A). While all LS proteins selected are expressed across Plasmodium 
spp., the synthetic optimized DNA vaccine constructs were matched for Plasmodium yoelii 
(Py), to reflect the planned challenge model.  
  In vitro expression of Py constructs in transfected 293T lysates was detected by 
western blot. Expression was confirmed for plasmids 2-5 by detection of the HA tag. 
Expression for plasmid 1, which lacked an HA tag, was confirmed by probing with post-
immune sera from mice immunized with the construct. GFP transfection was used as a 
negative control (Figure 2.1B).  
Py LS vaccine constructs delivered individually elicit a robust and 
polyfunctional T cell response 
To assess the cellular immune response to LS antigen vaccination, groups of 5 mice 
were immunized 4 times at 3-week intervals with one of the five constructs individually, or 
the empty vector pVax as a negative control. One week after final immunization 
splenocytes were collected for immune analysis and antigen specific cytokine production 
was assessed by IFNγ ELISPOT and flow cytometry. All 5 constructs induced detectable 
IFNγ cellular responses with EXP1_PFN and ICP being the highest inducers. EXP2 and 
UIS3 induced lower, but still robust levels of IFNγ secreting cells, and TMP21 induced 
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readily detectable, but the lowest, levels of IFNγ secreting cells (Figure 2.2A). The 
functional profile of antigen specific CD4+ (Figure 2.2B) and CD8+ (Figure 2C) T cells was 
analyzed by flow cytometry. Mono-, double-, and triple-positive CD4+ and CD8+ T cells 
releasing the cytokines IFNγ, TNFα, and IL-2 are shown. CD4+ T cells responded most 
highly to EXP1, EXP2, ICP, and UIS3. In contrast, CD8+ T cells responded most highly to 
PFN and EXP2. As expected, ELISPOT and flow cytometry responses in mice immunized 
with the empty vector control, pVax, were negligible (Figure 2.2). 
Co-formulated Py LS vaccines delivered with and without plasmid IL-33 
adjuvant elicit a robust and polyfunctional T cell response  
To investigate the immunogenicity of co-formulated vaccine constructs groups of 5 
mice were immunized 4 times at 3-week intervals with combinations of constructs 
(EXP1_PFN alone, EXP2 and ICP, TMP21 and UIS3, and all constructs together) with 
and without the molecular adjuvant pIL-33 all delivered in a single injection site. 
Splenocytes were collected for analysis of the cellular immune response using IFNγ 
ELISPOT and flow cytometry. All immunization groups saw an upwards trend in IFNγ 
ELISPOT responses with the addition of pIL-33 (Figure 2.3A). The functional profile of 
CD4+ (Figure 2.3B, D, E, and F) and CD8+ (Figure 2.3C, G, H, and I) T cells was analyzed 
by flow cytometry. In the mice immunized with EXP1_PFN alone, CD4+ T cells respond 
more highly to EXP1 and this phenotype is enhanced in the adjuvanted group (Figure 
2.3D). By contrast, as seen in Figure 2.3G, CD8+ T cells respond more highly to PFN, and 
this phenotype is also enhanced in the adjuvanted group. In mice immunized with EXP2 
+ ICP, CD4+ T cells responded quite similarly to EXP2 and ICP; however, in the
adjuvanted group the EXP2 response was preferentially increased (Figure 2.3E). CD8+ T 
cells responded more highly to EXP2; however, this phenotype was not recapitulated in 
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the adjuvant group (Figure 2.3H). In the mice immunized with TMP21 + UIS3, CD4+ T 
cells responded more highly to UIS3 (Figure 2.3F), a phenotype that did not change with 
the addition of pIL-33, whereas CD8+ T cells responded more highly to TMP21 (Figure 
2.3I). As expected, ELISPOT and flow cytometry responses in mice immunized with the 
empty vector control, pVax, or pIL-33 alone were negligible (Figure 2.3A, B, and C).   
Py LS antigen vaccination elicits a robust and polyfunctional antigen specific T 
cell response in the liver which is enhanced with the addition of plasmid IL-33 
The functionality of liver localized antigen specific T cells was investigated using the 
EXP1_PFN construct, as EXP1_PFN consistently produced the most robust T cell 
response. Mice were immunized 3 times at 3-week intervals with the EXP1_PFN construct 
with and without pIL-33. One week after the final immunization lymphocytes were isolated 
from both liver and spleen of immunized mice and their phenotype and functional capacity 
was measured using flow cytometry and ELISPOT assays. The percentage of CD8+ cells 
in the liver expressing CXCR6, a chemokine receptor important for trafficking to the liver87, 
was significantly increased from 40% without co-delivery of pIL-33 to 60% with the addition 
of pIL-33 (Figure 2.4A) while the expression of CXCR6 on CD8+ cells in the spleen was 
10-fold lower (Figure 2.4B) than that on CD8+ cells in the liver. This suggests an
improvement of trafficking to the liver with the addition of pIL-33. As seen previously, the 
addition of pIL-33 increased antigen specific IFNγ ELISPOT responses in the spleen 
(Figure 2.4D) and interestingly, also in the liver (Figure 2.4C). Further investigation of the 
functionality of the liver localized T cells using flow cytometry revealed that pIL-33 not only 
increased the percentage of IFNγ+TNFα+IL-2+ (triple positive), IFNγ+, and IL-2+ CD4+ 
cells (Figure 4G) and IFNγ+ CD8+ (Figure 2.4H) cells from the spleen, but also increased 
the percentage of IFNγ+ CD4+ (Figure 2.4E) and CD8+ (Figure 2.4F) cells from the liver. 
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Vaccine delivered with and without adjuvant elicits antigen-specific antibody 
responses 
Vaccine induced antibody production was assayed by immunofluorescence. Hepa1-
6 cells, were transfected with each DNA vaccine construct. Two days post transfection the 
cells were probed with post-immune sera from mice immunized with the respective DNA 
construct (with or without pIL-33) and probed with a fluorescently tagged secondary 
antibody. Mice immunized with EXP1_PFN showed the most positive staining indicating 
the highest antibody response. EXP2, ICP, and UIS3 showed intermediate antibody levels 
and TMP21 showed the lowest levels of antibody induction (Figure 2.5). The addition of 
pIL -33 did not appear to alter the amount of detectable antibody binding (Figure 2.5). 
However, we cannot conclude whether or not this antibody response is important for the 
observed immunity, as it is unknown whether these Plasmodium proteins would be 
available for antibody binding in a physiologically relevant context. It is important to note 
that while this assay shows the presence of antibodies elicited by vaccination, it does not 
provide quantitative information on antibody level or titer. 
Plasmodium LS synDNA vaccine is protective against malaria infection in a 
mouse model 
To assess the ability of these DNA vaccine constructs expressing LS malaria antigens 
to protect against malaria, groups of 7-8 mice were immunized 4 times at 3-week intervals 
with combinations of constructs (EXP1_PFN alone, EXP2 and ICP, TMP21 and UIS3, and 
all constructs together) with and without the molecular adjuvant pIL-33, and then 
challenged 9 weeks later with intravenous delivery of 250 infectious P. yoelii sporozoites. 
Blood was collected daily following sporozoite injection for blood smears to check for the 
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presence of blood stage parasites, i.e. patency (Figure 2.6A). All empty vector and pIL-33 
alone immunized animals had visible blood stage parasites 4 days after challenge. 71-
88% of animals immunized with DNA vaccine delivered without adjuvant were completely 
protected from patency, with parasitemia in the few animals who were not protected being 
delayed 1.5-2 full days. 100% of animals immunized with any combination of constructs 
in addition to pIL-33 were completely protected from blood stage parasitemia indicating 
sterile protection in these groups (Figure 2.6B). Examples of the blood smears from each 
group showing the presence of blood stage parasites only in the pVax and pIL-33 alone 
groups are shown in Figure 2.6C. 
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Discussion 
Synthetic DNA delivered by adaptive electroporation (EP) is a particularly 
attractive vaccine platform for a LS antigen malaria vaccine because of its ability to 
induce robust CD8+ T cell responses. In clinical studies, synDNA vaccines delivered 
with EP have proven highly effective in small and large animal models of infectious 
disease and cancer, and have demonstrated the ability to drive a tissue infiltrating 
population of antigen specific CD8 T cells157. In recent years, DNA vaccines for HPV157, 
HIV161,162, Zika155, and Ebola163 among others have moved into human clinical trials. 
Here, I present a novel approach using synthetic DNA vaccination with LS antigens in 
conjunction with a plasmid encoded molecular adjuvant IL-33 which together drive 
antigen specific liver associated CD8 T cells and achieve complete protection from blood 
stage disease in a virulent Plasmodium sporozoite challenge in the mouse model.  
This study demonstrates that a synDNA vaccine targeting liver stage 
Plasmodium antigens drives an antigen specific liver localized T cell population. Further, 
this study illustrates the potential efficacy of a synDNA vaccine platform targeting liver 
stage proteins in providing protection from malaria infection in this model. I show that a 
synDNA vaccine targeting EXP1, PFN, EXP2, ICP, UIS3, and TMP21, in combination or 
alone, elicits a robust T cell response, as well as the production of antibodies against 
liver stage malaria. The use of the molecular adjuvant pIL-33 increases the immune 
response to vaccine and results in 100% protection from blood stage disease after 
sporozoite challenge, where non adjuvanted vaccine results in 70-88% protection from 
blood stage disease. A potential contributor to this increased protection in the 
adjuvanted groups is the increase in antigen responsive liver associated T cells, as well 
as their polyfunctionality as demonstrated by enhanced cytokine poly-positivity in 
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adjuvanted groups. Additional focus on LS antigens as a component of a malaria 
vaccine is warranted, potentially in combination with sporozoite antigens such as CSP. 
RTS,S and R21 combinations might be particularly interesting164–166. Altogether, the data 
suggest cell-mediated immunity as well as antibodies should be considered when 
designing anti-malarial vaccines and support the continued examination of liver stage 
antigens as components of a prophylactic vaccine. 
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Materials and Methods 
Construct design 
Protein sequences for selected Plasmodium antigens were accessed on 
PlasmoDB, the Plasmodium genomics resource (EXP1: PY04421, PFN: PY03207, 
EXP2: PY05892, ICP: PY17X_0816300, TMP21: PY06414, UIS3: PY03011). While all 
antigens selected are expressed across Plasmodium spp., the vaccine constructs were 
matched to Plasmodium yoelii 17X (Py), to reflect the planned challenge model, which 
was P.yoelii 17X-NL (non-lethal) strain. The synthetic DNA vaccine constructs were 
codon optimized for mice and humans and were incorporated into a modified pVax 
vector with an IgE leader sequence, and an HA tag where indicated in Figure 2.1.  
Western blot 
In order to assess in-vitro expression of the vaccine constructs, 293T cells 
(ATCC® CRL-3216™) were plated in 6-well plates at 0.5-0.7x106 cells per well in 2 mL 
DMEM (Gibco) + 10% FBS and incubated overnight at 37 °C in 5% CO2. Cells were 
transfected with 5 μg DNA using TurboFectin 8.0 transfection kit and incubated for 48 hr. 
48 hours after transfection, supernatants and lysates were collected for western blot 
analysis. Samples were prepared with NuPAGE LDS Sample Buffer, 10X Reducing 
Agent, and deionized water. Sample mixture was incubated at 70 °C for 10 minutes. 25 
μl of sample was loaded per well onto an Invitrogen NuPAGE Bis-Tris Gel in 1X NuPage 
MOPS running buffer. The gel was run for 150 V for 50 min. Protein was transferred to a 
methanol activated PVDF membrane using the iBlot 2 Dry Blotting System (Life 
Technologies). The membrane was blocked for 1 hr at room temperature with Li-Cor 
Odyssey Blocking Buffer followed by overnight incubation at 4 °C  with primary antibody. 
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Primary antibody was either an anti-HA antibody (ThermoFisher) to detect expression of 
the constructs which contain an HA tag, or post-immune sera collected from mice 
immunized with the construct to detect expression of the EXP1_PFN construct which did 
not have an HA tag. After washing, the membrane was incubated for 1 hr at room 
temperature with IRDye labeled secondary antibody (Li-Cor) and then imaged using an 
Odyssey CLx imager. 
Immunization and CELLECTRA electroporation 
Female BALB/C mice were ordered from the Jackson Laboratory aged 6-8 
weeks and were housed in the Wistar Institute Animal Facility. Mice were immunized 
with 25 μg DNA vaccine construct with or without 30 μg of plasmid pIL-33 delivered 
intramuscularly using the CELLECTRA 3P adaptive constant current electroporator167. 
When mice were immunized with a cocktail of antigens, 25 μg of each DNA vaccine 
construct was used. Depending on the experiment, mice were immunized 4 or 3 times at 
3-week intervals. Blood was collected 1 week post each vaccination for sera isolation.
One week post final immunization mice were euthanized and splenocytes and 
hepatocytes were collected for immune analysis.  
Immune Cell Isolation 
After euthanasia, liver and spleen tissue were removed for immune cell isolation. 
Before liver excision, the hepatic portal vein exiting the liver was cut and 5-10 ml of cold 
PBS solution was administered through the left ventricle to profuse the liver until 
blanched. Once perfused the liver was removed and placed in cold complete media 
(DMEM + 10% FBS + 20 mM HEPES + 1X Pen/Strep). Livers were quickly 
homogenized for 1 min at normal speed using a Stomacher 80 (Seward). Homogenates 
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were transferred to 6-well plates with 10 ml of digest media (DMEM + 20 mM HEPES + 
0.1 mg/ml Collagenase 4 + 0.02 mg/ml DNase) added and plates were incubated at 37 
°C for 30 min. Cells were filtered through a 100 μm mesh strainer, rinsed with PBS, and 
then centrifuged at 300 rpm for 1 min. The supernatant containing hepatocytes was 
transferred to a new tube and spun down for 5 min at 1500 rpm. The cell pellet was 
resuspended in 40% Percoll (Sigma-Aldrich), underlaid with 80% Percoll, and spun at 
3000 rpm for 20 min with slow acceleration and deceleration. Hepatocytes at the 
interface of the two Percoll layers were removed and diluted in complete media, then 
counted using a COUNTESS II (Invitrogen) and trypan blue (Gibco). 
Spleens were removed and placed in RPMI + 10% FBS + 1X Pen/Strep (R10). 
Spleens were homogenized for 1 min on high using a Stomacher 80. The cell solution 
was filtered through a 100 μm strainer and spun down for 10 mins at 1200 rpm. Cells 
were resuspended in 5 ml ACK lysis buffer (Gibco) and incubated for no more than 5 
min. After washing with PBS, cells were spun for 10 min at 1200 rpm. Splenocytes were 
then resuspended in 20 ml of R10 and counted. 
ELISPOT 
Mouse IFN-γ ELISpot PLUS (Mabtech) plates were used as directed. Briefly, 
plates were washed with PBS and blocked with R10 for 30 min. Wells were seeded in 
triplicate with 200,000 cells in 100 μl R10. Cells were stimulated with peptide pools of 
15mers overlapping by 11 amino acids spanning the entire vaccine antigen at a final 
concentration of 5 μg/ml per peptide. R10 and Concanavalin A were used as negative 
and positive controls, respectively. Plates were incubated for 18 hr at 37°C with 5% CO2. 
Plates were developed as directed, scanned, and counted using a CTL ImmunoSpot S6 
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Universal Analyzer. Data was exported to Microsoft Excel and GraphPad Prism 8 for 
analysis.  
Flow cytometry 
Wells were seeded with 1,000,000 cells in 100 μl of R10. Cells were stimulated 
with peptides at a final concentration of 5 μg/ml per peptide in the presence of Protein 
Transport Inhibitor (eBioscience). R10 and Cell Stimulation Cocktail (eBioscience) were 
used as negative and positive controls, respectively. Plates were incubated for 6 hr at 37 
°C with 5% CO2. Following incubation, cells were washed with PBS, and stained with 
Live/Dead fixable aqua dead cell stain kit (ThermoFisher) in PBS. Cells were then 
stained for extracellular markers in 1% FBS in PBS (FACS buffer), fixed and 
permeabilized with BD Fix/Perm, stained for intracellular markers and cytokines in BD 
perm/wash, resuspended in FACS buffer, and run on BD LSRII flow cytometer (BD 
Biosciences). Splenocytes and hepatocytes were stained with following panel: LiveDead 
Aqua (Invitrogen, L34957), CD19-V450 (BDHorizon, 560375), CD3-AF700 (BioLegend, 
100216), CD4-FITC (BD Pharmingen, 553047), CD8-BV605 (BioLegend, 100744), IFNγ-
APC (BioLegend, 505810), TNFα-PE (eBioscience, 12-7321-82), IL-2-PE-Cy7 
(eBioscience, 25-7021-82) and CXCR6-BV421 (Biolegenend, 151109). Gates were set 
using FMOs for each stain. Data were exported and analyzed in GraphPad Prism 8.1.1. 
Immunofluorescence 
Hepa1-6 cells (a cell line derived from mouse liver cells, ATCC® CRL-1830™) 
were plated on pre-coated Poly-D-Lysine (Corning) 8 chambered wells at 100,000 cells 
per well in 400 μl DMEM (Gibco) + 10% FBS and incubated overnight at 37 °C in 5% 
CO2. Cells were transfected with 1 μg DNA using Thermofisher Lipofectamine 3000 
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transfection kit and incubated for 48 hr. Media was removed, and cells were washed 
twice with PBS (Gibco) for 5 min and then fixed with 2% PFA in PBS for 5 min. Cells 
were again washed twice with PBS followed by blocking in 5% goat serum + 0.05% 
Tween-20 for 1 hr at room temperature followed by two 5 min PBS washes. Cells were 
incubated with 500 μl pooled mouse sera at a 1:50 dilution in 1% BSA + 0.05% Tween-
20 in PBS buffer at room temp for 1 hr. After washing three times with PBST (0.05% 
Tween-20 in PBS) for 5 min each, cells were incubated with 300 μl of secondary 
antibody diluted in 1% BSA + 0.05% Tween-20 in PBS buffer at room temp for 1 hr. 
Cells were washed with PBST for 5 min, then incubated with DAPI (Hoechst 33342 
Fluorescent Stain, Thermo Scientific) at a 1:5,000 dilution in PBST for 5 min, followed by 
a final wash with PBST to remove unbound DAPI stain. Cells were imaged using a Leica 
TCS SP5 confocal microscope.  
Mosquito feeding and sporozoite extraction 
Six-to-eight-week-old female Swiss Webster (SW) mice (purchased from Envigo, 
Indianapolis, IN) were used for mosquito feeding experiments to generate salivary gland 
sporozoites for challenge studies. All animal handling was conducted according to the 
approved protocols of the Institutional Animal Care and Use Committee (IACUC) of 
Tulane University (Protocol # 4258R). Mosquito feeding experiments were conducted 
with P. yoelii 17X-NL wild-type parasites as previously described168–170. Briefly, SW mice, 
treated with phenylhydrazine, are injected intravenously with 1 million blood stage 
parasites, and on day 3 post infection an exflagellation assay is used to confirm the 
availability and formation of P. yoelii male microgametes. Mosquito feeding is conducted 
by allowing about 150 female mosquitoes or less to feed on a mouse anesthetized with 
ketamine/xylazine for 15 min. Salivary gland sporozoite extraction was conducted by 
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dissection of the salivary glands of infected female mosquitoes at day 14 or 15 post 
mosquito feeding (pmf) in RPMI incomplete medium, as previously described 81,171,172. 
Collected salivary glands were mechanically disrupted with a pestle and the salivary 
gland sporozoites were counted using a hemocytometer. Doses of 250 sporozoites in 
150 µl incomplete RPMI were prepared as previously described86,87,137.  
Challenge study 
Six-to-eight-week-old female BALB/cJ mice (purchased from Jackson 
Laboratories, Bar Harbor, ME) were used for challenge experiments. Mice were put 
under a red heating lamp 5-10 min before injection. Each dose of 250 sporozoites was 
loaded in 27G insulin syringes and was injected intravenously in the tail vein of 
immunized mice. Giemsa-stained thin blood smears were checked every day (at least 50 
whole microscopy fields at 1000x) for blood stage parasites, starting from day 3 until day 
10 post infection81,171,172.  
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Figures 
Figure 2.1 DNA vaccine construct design and in vitro expression. (A) Schematic 
diagram of Plasmodium yoelii (Py) gene inserts used to generate the codon-optimized 
DNA vaccine constructs. The schematic details leader sequence (IgE), gene insert, and 
presence or absence of HA tag. All constructs with the exception of EXP1_PFN contain 
an HA tag. (B) Expression of Py proteins detected by SDS-polyacrylamide gel 
electrophoresis and western blot of lysate from transfected 293T cells. Protein 
expression was detected by probing for the HA tag when present with an anti-HA 
antibody, or with immune sera from immunized mice for the EXP1_PFN plasmid. 




Figure 2.2 Functional profile of cellular immune responses elicited by 
individual Py DNA vaccines in mice. Mice were immunized 4 times at 3-week 
intervals with the indicated co-formulation of vaccine constructs with and 
without plasmid IL-33. Splenocytes were collected 1 week after the final 
immunization. (A) The Py antigen-specific cellular immune response measured 
by IFNγ ELISPOT of splenocytes 1 week after final immunization with the 
indicated Py DNA vaccine. Cells were stimulated for 18 hr with peptide pools 
encompassing the entire protein. A one-way ANOVA with Dunnet’s multiple 
comparison test was used to compare each vaccine group to the pVax control 
group. (B,C) The Py antigen-specific cytokine production profile of CD4+ (B) 
and CD8+ (C) T cells from spleens 1 week after the final immunization with the 
indicated Py DNA vaccine. Cells were stimulated with pooled peptides for 6 
hr, stained for intracellular production of IFNγ, TNFα, and IL-2, and then 
analyzed by flow cytometry. The bar graph shows subpopulations of mono-, 
double-, and triple-positive CD4+ and CD8+ T cells. A 2-way ANOVA with 
Tukey’s multiple comparisons test was used to compare cytokine production 
between each vaccine group and the pVax control group. Asterix color 
indicates which cytokines were significantly different between vaccine and 
control. * = p < 0.05, ** p < 0.01, *** = p < 0.001, **** = p < 0.0001. Values 
represent mean responses in each group (n = 5) ± SEM. 
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Figure 2.3 Functional profile of cellular immune responses elicited by co-formulated Py 
DNA vaccines in mice. Mice were immunized 4 times at 3-week intervals with the 
indicated co-formulation of vaccine constructs with and without plasmid IL-33. 
Splenocytes were collected 1 week after the final immunization. Immunization groups 
were: All vaccine constructs with or without IL-33, EXP1_PFN (exported protein 
1_profilin) with or without IL-33, EXP2 (exported protein 2) and ICP (inhibitor of cysteine 
proteases) with or without IL-33, and TMP21 (transmembrane protein 21) and UIS3 
(upregulated in infective sporozoites-3) with or without IL-33. (A) The Py antigen-specific 
cellular immune response induced by the indicated Py DNA vaccine co-formulation 
measured by IFNγ ELISPOT. Cells were stimulated for 18 h with peptide pools 
encompassing the entire protein. T-tests were used to compare groups with and without 
IL-33. (B–I) The Py antigen-specific cytokine production profile of CD4+ (D–F) and CD8+ 
(G–I) T cells induced by the indicated Py DNA vaccine co-formulation. Cells were 
stimulated with pooled peptides for 6 h, stained for intracellular production of IFNγ, 
TNFα, and IL-2, and then analyzed by flow cytometry. The bar graph shows 
subpopulations of mono-, double-, and triple-positive CD4+ and CD8+ T cells. Two-way 
ANOVAs with Tukey’s multiple comparison test were used to compare vaccine groups 
against the same group adjuvanted with IL-33. Asterix color represents the corresponding 
cytokine groups. * = p < 0.05, ** p < 0.01, *** = p < 0.001, and **** = p < 0.0001. Values 
represent the mean responses in each group (n = 5) ± SEM. 
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Figure 2.4 Synthetic DNA vaccines drive antigen-specific liver resident T cells. Mice 
were immunized 3 times at 3-week intervals with the EXP1_PFN vaccine construct with 
and without plasmid IL-33. Lymphocytes were isolated from liver and spleen 1 week 
after the final immunization. (A, B) The proportion of liver resident/homing CD8+ T 
cells. Lymphocytes from liver (A) or spleen (B) were stained for extracellular CXCR6 
and analyzed by flow cytometry. Paired t-tests were used to compare % CXCR6 
positivity on CD3+CD8+ T cells across vaccine groups and against the pVax control. (C-
D) The Py antigen-specific cellular immune response in liver (C) and spleen (D) 
measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools 
encompassing the entire protein. T-tests were performed to compare IFNγ production 
across vaccination groups and against the pVax control. The Py antigen-specific 
cytokine production profile of CD4+ (E,G) and CD8+ (F,H) T cells from the liver (E-F) 
and spleen (G-H). Cells were stimulated with pooled peptides for 6 hr, stained for 
intracellular production of IFNγ, TNFα, and IL-2, and then analyzed by flow cytometry. 
The bar graph shows subpopulations of mono-, double-, and triple-positive CD4+ and 
CD8+ T cells. 2-way ANOVAs with Tukey’s multiple comparison test were used to 
compare cytokine production across vaccination groups and against the pVax control. 
The pie chart shows the proportion of each cytokine subpopulation. Values represent 
mean responses in each group (n = 5) ± SEM. 
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Figure 2.5 Antibodies elicited by Py 
DNA vaccines in mice. Hepa1-6 cells were 
transfected with the DNA vaccine construct 
listed on the left. Cells were then probed 
with pooled mouse post-immune sera 
collected 1 week after the last 
immunization. An anti-mouse-IgG-AF488 
was used as a secondary antibody to detect 
the presence of anti-Py antigen antibodies. 
DAPI staining shows cell nuclei. White text 
in the top left corner of each field indicates 
post-immune sera vaccine group. 
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Figure 2.6 DNA vaccine expressing Py LS antigens provides protection from blood stage 
disease after sporozoite challenge. (A) Vaccine and challenge timeline. Balb/c mice were 
immunized 4 times at 3-week intervals with the indicated vaccine co-formulations. 
Immunization groups were: All vaccine constructs with or without IL-33, EXP1_PFN with or 
without IL-33, EXP2 and ICP with or without IL-33, and TMP21 and UIS3 with or without IL-
33. Mice were then challenged by injection of 250 P. yoelii sporozoites. Blood smears were
examined daily for signs of blood stage disease. (B) Survival curves showing protection from
evidence of blood stage parasites. Log-rank tests were used to compare groups and p-values
less than the Bonferroni-corrected threshold are indicated. * = p < 0.05, ** p < 0.01, *** = p <
0.001, **** = p < 0.0001. (C) Example blood smears from each group. Red arrows indicate
blood stage parasites.
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CHAPTER 3: The importance of anti-CSP antibodies in 
protection from Malaria 
Introduction 
Chapter 2 addressed our efforts developing a pre-erythrocytic vaccine targeting 
liver stage antigens, which had the goal of eliciting cell mediated immunity targeting 
infected hepatocytes. This chapter will focus on our efforts developing a pre-erythrocytic 
vaccine to intercede before the parasite even establishes infection in hepatocytes; the 
studies outlined in this chapter aimed to develop an anti-sporozoite antibody response to 
prevent sporozoite invasion of hepatocytes, and thus prevent progression to 
symptomatic disease.  
As discussed in chapter 1.4, RTS,S/AS01 (RTS,S) is one of the longest studied 
candidate vaccines, and is focused on generating immunity to CSP, the 
circumsporozoite protein of Plasmodium falciparum (Pf). RTS,S is a recombinant 
protein-based vaccine comprised of a fragment of CSP containing a section of the 
repeat region, and the T cell epitopes of the c-terminus attached to the Hepatitis B 
surface antigen protein, and delivered with additional HbsAg to encourage the formation 
of virus-like-particles in yeast, which are then harvested and administered with an 
adjuvant to humans to generate a T cell and antibody response. This is the only vaccine 
to show significant reduction in malaria in young children living in endemic regions. A 
phase 3 trial which spanned 5 years demonstrated that children aged 5-17 months who 
received 4 doses of RTS,S had a 39% reduction in malaria cases, and a 29% reduction 
in severe malaria cases over 4 years of follow-up67. After positive recommendations by 
WHO advisory boards, three countries, Ghana, Kenya, and Malawi began introducing 
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RTS,S in 201927. In the coming years, the Malaria Vaccine Implementation Programme 
(MVIP) will assess the feasibility of administering the recommended 4 doses of the 
vaccine in children, the potential role in reducing childhood death, and the safety of 
RTS,S in the context of routine use68 as well as in specific important subpopulations.  
An important advance in malaria vaccines is the development of a novel 
polyvalent immunogen R21, a recent anti-malaria vaccine candidate, which builds on the 
knowledge gained from RTS,S. In contrast to RTS,S, R21 delivers a higher ratio of CSP 
to the Hepatitis B surface antigen (HBVsAg), which is in a 1 to 1 ratio as opposed to the 
1 to 4 ratio of RTS,S5.  Thus far R21 has proven to be well tolerated and immunogenic in 
early trials, as well as protective in a controlled human malaria infection study 
(CHMI)69,70. The correlates of immunity which have emerged from these malaria 
vaccines support the importance of anti-CSP antibodies primarily but also suggest a role 
for T cells for imparting protection from Plasmodium infection67,69–74.  
The circumsporozoite protein (CSP) has long been a vaccine candidate of 
interest. CSP is the major component of surface proteins on sporozoites, forming a 
dense coat on the parasite during this stage of the life cycle173,174. CSP is composed of 
three regions, (1) an N-terminus that binds heparin sulfate proteoglycans, (2) a four 
amino acid repeat region, and (3) a C-terminus that contains a thrombospondin-like type 
I repeat (TSR) domain. Native CSP on the surface of sporozoites appears as a 
glycosylphosphatidylinositol-anchored, flexible rod-like protein175,176. The central repeat 
region contains the immunodominant B cell epitope177,178. The C-term contains the TSR, 
T cell epitopes, as well as B cell epitopes179,180. The N-terminus region is also of 
importance, as it has been shown to be involved in liver attachment181, and interacts with 
liver cells through heparin sulfate; antibodies against this region have been shown to be 
inhibitory in a sporozoite invasion assay182. As for overall structure, it has been shown 
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that CSP forms a long, flexible, rod-like superhelix composed of regular β-turns175,176. 
However, this structure undergoes conformational changes during the parasite’s life 
cycle36. As referenced above, CSP interacts with heparan sulfate proteoglycans on the 
surface of hepatocytes during the invasion process35,183,184. This interaction is contingent 
on processing of the N-terminus and the subsequent conformation change36. Further, a 
synthetic peptide corresponding to L86 to G100 blocks salivary gland invasion, showing 
the biological importance of the n-terminal domain185. The processing of CSP by a 
parasite cysteine protease, and subsequent cleavage, is specifically associated with the 
decision between productive invasion and cell transversal35,174, as the proteolytic 
cleavage of CSP regulates the switch to an open adhesive confirmation, whereas the 
masking of this domain maintains the sporozoite in a migratory state173.  
This knowledge of the importance of all three domains of CSP, as well as the 
importance of its confirmation, shaped our decisions for construct design. To that end, 
five synDNA constructs were designed with variations hypothesized to provide relevant 
expression and folding, or for testing the importance specific domains of CSP for 
inducing protection (Figure 3.1). The construct “3D7” contains the unadulterated full 
length native CSP sequence from the Pf 3D7 strain. The construct “GPI1” contains the 
CSP sequence from the Pf 3D7 strain, with a mammalian GPI anchor substituted in for 
the native protozoan GPI anchor. The construct “ΔGPI” contains the native CSP 
sequence from the Pf 3D7 strain without a GPI anchor. The construct “TM” contains the 
CSP sequence from the Pf 3D7 strain with a mammalian transmembrane domain 
substituted in for the native protozoan GPI anchor. The construct “DD2_3D7” contains 
the N-terminus region of CSP from the Pf DD2 strain, linked to the n-terminus region of 
CSP from the Pf 3D7 strain. These five variations on CSP tested soluble vs secreted 
forms, different cell membrane attachment approaches, oligomerization, and the 
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importance of the domains of CSP in immunization and challenge studies. Mice 
immunized with 3D7, dGPI, GPI1, or TM all developed robust antibody responses 
against both recombinant CSP (rCSP) as well as the NANP7 peptide, whereas mice 
immunized with DD2 had a negligible antibody response. Additionally, all 5 constructs 
induced IFNγ cellular responses with ΔGPI being the highest inducer. Finally, mice 
immunized with ΔGPI had the highest inhibition of liver stage infection in a murine 
challenge model. The vaccine with the highest immunogenicity and most robust 
protective efficacy was ΔGPI.  
Additionally, based on previous work in the lab demonstrating the ability of DNA 
launched nanoparticles to assemble in vivo186, I developed mimics of the leading CSP 
vaccines, RTS,S and R21 (both recombinant protein based polyvalent vaccines), and 
tested them side by side with our other DNA vaccines. SynDNA RTS,S (dRTS,S) and 
synDNA R21 (dR21) displayed similar immunogenicity and protective efficacy to their 
protein counterparts. Both dRTS,S and dR21 elicited anti-CSP antibodies, and only 
dRTS,S elicited anti-HBsAg antibodies, where dR21 did not, recapitulating what has 
been seen in prior studies69. Additionally, both dRTS,S and dR21 vaccinated mice 
produced IFNy in response to stimulation with CSP antigen. Consequently, dRTS,S and 
dR21, as well as ΔGPI, demonstrated high protective efficacy against a rigorous 
infectious mosquito bite murine malaria challenge. 
Thus we observe that a uniquely designed synthetic DNA vaccine, ΔGPI, as well 
as genetically encoded RTS,S and R21 form polyvalent protein structures which elicit a 
robust anti-CSP antibody response, as well as a T cell response which was associated 
with protection from Plasmodium infection. Additional study of this approach appears 
warranted based on our demonstration of robust immunogenicity in the putative 
correlates of protection for malaria infection, specifically the high titer antibody response, 
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synDNA CSP vaccine construct design and in vitro expression 
Five synDNA constructs were designed with variations hypothesized to increase 
immunogenicity. All constructs target Plasmodium falciparum (Pf). Each construct was 
synthesized and then inserted into a pVax backbone, with an added IgE leader 
sequence as described128. The construct “3D7” contains the unadulterated full length 
native CSP sequence from the Pf 3D7 strain. The construct “GPI1” contains the CSP 
sequence from the Pf 3D7 strain, with a mammalian GPI anchor substituted in for the 
native protozoan GPI anchor. The construct “ΔGPI” contains the native CSP sequence 
from the Pf 3D7 strain without a GPI anchor. The construct “TM” contains the CSP 
sequence from the Pf 3D7 strain with a mammalian transmembrane domain substituted 
in for the native protozoan GPI anchor. The construct “DD2_3D7” contains the N-
terminus region of CSP from the Pf DD2 strain, linked to the n-terminus region of CSP 
from the Pf 3D7 strain. These five variations on CSP tested soluble vs secreted forms, 
different cell membrane attachment approaches, and the importance of domains of CSP 
in immunization and challenge studies. In vitro expression of each construct was verified 
by western blot. Because the detection Ab used was directed against the repeat region, 
the construct DD2 would not be readily detected by this method (Figure 3.1B). The 
synDNA vaccine construct ΔGPI exhibited the highest expression in the supernatants 
collected from transfected cells (Figure 3.1C). This may indicate a superior ability to be 
secreted from transfected myocytes in vivo, and thus superior immune activation, though 
further study is needed.  
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synDNA CSP vaccine constructs elicit a robust immune response 
To assess the immunogenicity of each unique construct, groups of five BALB/c 
mice were immunized with 25 µg of vaccine four times, three weeks apart (week 0, 3, 6, 
and 9) (Figure 3.2A). pVax was included as an empty vector (negative) control. Sera 
was collected to assess the antibody response. Previous work has shown that 
antibodies are of critical importance for targeting CSP, particularly the NANP region187. 
The sera from immunized mice was used as a primary antibody to probe ELISA plates 
which had been coated with either recombinant CSP, or the NANP peptide alone. The 
monoclonal antibody 2A10188 was used as a control. Mice immunized with 3D7, ΔGPI, 
GPI1, or TM all developed robust antibody responses against both rCSP and the NANP 
peptide. Mice immunized with DD2 induced a negligible antibody response, and those 
immunized with the empty vector control had no antibody response (Figure 3.2B-C). In a 
parallel experiment, splenocytes were collected one week after final immunization for 
immune analysis and antigen specific cytokine production was assessed by IFNγ 
ELISPOT. All 5 constructs induced IFNγ cellular responses with ΔGPI being the most 
potent. 3D7, GPI1, and TM induced lower, but still robust levels of IFNγ secreting cells, 
and DD2 induced readily detectable, but the lowest, levels of IFNγ secreting cells (Figure 
3.2D). The bulk of the IFNγ response is directed against the n-terminus of CSP, follow in 
reactivity by the c-terminus. The NANP repeat region induced a low level of IFNγ. 3D7, 
the only construct designed to contain a Pf GPI anchor, did elicit a response to the GPI 
anchor (Figure 3.2D).  
synDNA CSP vaccine constructs are protective against IV sporozoite Pf challenge 
Groups of five BALB/c mice were immunized with 25 µg of vaccine four times, 
three weeks apart (weeks 0,3,6,9) as in Figure 3.2A. Two weeks after the last boost, 
mice were inoculated with 250 sporozoites IV. Immunized and non-immunized BALB/c 
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mice were challenged with P.berghei sporozoites expressing both the P.falciparum 
circumsporozoite protein (CSP) and luciferase. 42 hours after intravenous injection of 
250 sporozoites, mice were intraperitoneally injected with 100 μl of D-luciferin (30 
mg/mL), anesthetized and liver luminescence was measured with the Perkin Elmer IVIS 
Spectrum Imaging System to assay liver loads. Inhibition of liver infection is expressed 
as a function of relative infection compared to naive mice. Mice immunized with ΔGPI 
have the highest inhibition of liver infection (64.17%) out of the immunized groups, while 
the positive control, which was 100 µg of the MAb 311187 delivered 16 hours before 
challenge showed an 80% inhibition of liver stage infection (Figure 3.2E-G). ΔGPI 
showed significant vaccine induced protective immunity in this challenge model (Figure 
3.2E-G).  
DNA encoded CSP polyvalent vaccines  
We were encouraged by these initial challenge results, and wanted to compare 
them to the important standards in the field (RTS,S and R21) which are more complex 
vaccine formulations, both of which form  polyvalent particles. However, research 
acquisition of the protein forms was limited. Thus to compare such more polyvalent 
forms, we moved to develop genetically encoded DNA vaccines in the form of dR21 and 
dRTS,S. The sequences for R21189 and RTS,S190 were retrieved, and then modified to 
include changes in RNA and codon bias, as well as the addition of an efficient IgE leader 
sequence, to generated dR21 and dRTS,S. The final constructs were inserted into a 
pVax backbone (Figure 3.3A). The dR21 construct is delivered in vivo as is, as it is a 
singular antigen fusion between the Hepatitis B surface antigen (HbsAg) and CSP. To 
assemble a mimic of RTS,S we designed two constructs, one encoding HbsAg and a 
second RTS construct. The final plasmids were mixed at a 1:4 ratio of RTS to HbsAg 
(Figure 3.3A) to mimic its production as a final protein particle antigen190. 
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Expression of each construct was studied by western blots of supernatants 
collected from transfected cells, using the anti-CSP monoclonal antibody 311 for 
detection. dR21 and dRTS,S both expressed in-vitro (Figure 3.3B). To elucidate whether 
dR21 and dRTS,S were forming nanoparticles similarly to their protein formulation 
counterparts, supernatants from transfected cells were run on a discontinuous sucrose 
gradient and separated by molecular weight via ultracentrifugation for 24 hours. The 
resulting gradient fractions were analyzed by western blot for CSP expression (Figure 
3.3C). We observed protein bands with high molecular weight from supernatants 
collected from both dRTS,S and dR21 transfected cells, that may correspond to higher-
order structures such as polyvalent particles. We also observed CSP in high molecular 
weight fractions of supernatants collected from ΔGPI transfected cells, suggesting that 
this vaccine construct is also capable of forming multimeric aggregates similar to 
dRTS,S and dR21. This phenomenon was not observed in supernatants collected from 
3D7 transfected cells, and thus may be a contributing factor behind the superior 
protection observed in Figure 3.2. To evaluate the biophysical properties of the high 
molecular weight fractions which contained CSP (Figure 3.3C), we analyzed relevant 
fractions with negative stain electron microscopy (nsEM). Higher-order structures 
ranging in diameter from 20nm to 50nm were observed in the high molecular weight 
fractions from dRTS,S, dR21, and ΔGPI transfected cells, and not in mock transfected 
cells (Figure 3.3D).  
Both dRTS,S and dR21 induced an potent IFNγ cellular response. Using 
separate peptide pools for mapping we observed that the majority of the CSP response 
to dRTS,S and dR21 was directed at the c-terminus region of CSP. Although the cellular 
response does target CSP, majority of the vaccine-induced cellular response was 
specific to HbsAg but not to CSP (Figure 3.4D). In contrast, immunization with ΔGPI only 
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elicits an IFNγ response against the CSP protein, and at a higher magnitude than dR21 
and dRTS,S (Figure 3.4C-D). However, this focusing of the cellular response onto the 
carrier protein did not impair the antibody response, as immunization with both dRTS,S 
and dR21 elicited robust anti-rCSP antibody titers. Comparison of the responses 
demonstrated that immunization with ΔGPI resulted in slightly higher Ab responses 
against recombinant CSP than dR21 and dRTS,S (Figure 3.4A). Neither ΔGPI nor dR21 
elicited an anti-HBsAg antibody response, whereas dRTS,S did (Figure 3.4B). The 
higher molar ratio of HBsAg in dRTS,S may  be responsible for this observation, 
however further study of these differences could generate additional insight.  
Polyvalent CSP constructs elicit a robust Ab response and are protective against 
a rigorous mosquito bite challenge model  
ΔGPI, the most potent construct from the initial CSP DNA vaccine study and 
challenge experiment, and the construct which demonstrated high-molecular weight 
aggregate formation along with dRTS,S and R21, were evaluated in a more rigorous 
mosquito bite malaria challenge model191. Groups of five BALB/c mice were immunized 
with 25 µg of vaccine four times, three weeks apart (weeks 0,3,6,9). Three weeks after 
the last immunization, the mice were challenged with Plasmodium berghei (Pb) 
transgenic parasites which express the full-length Plasmodium falciparum 
circumsporozoite protein (PfCSP), as well as luciferase as a reporter for liver parasite 
load. This parasite is denoted from this point on as PbPfLuc. A cage of Anopheles 
stephensi mosquitoes, 20 days after blood feeding on PbPfLuc infected mice was found 
to be 90% infected with PbPfLuc. Based on this calculation that 90% of the mosquitos in 
the cage were infected, 5 mosquitoes were required to challenge mice to ensure robust 
infection by mosquito bites, as described192. Mice were anesthetized with 2% Avertin 
prior to challenge. Mosquitoes were allowed to feed on the animals for ~10 minutes. 
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After feeding, the number of mosquitoes positive for a blood meal were determined 
(Figure 3.5A).  
42 hours after challenge, mice were intraperitoneally injected with 100 μl of D-
luciferin (30 mg/mL), anesthetized and liver luminescence was measured by using the 
Perkin Elmer IVIS Spectrum Imaging System to assay liver parasite loads. Inhibition of 
liver infection is expressed as a function of relative infection compared to naive mice. 
Mice immunized with ΔGPI have the highest inhibition of liver infection observed in 
vaccinated groups (84.6%), while the positive control, 100 ug of the MAb 311 
demonstrates an 88.7% inhibition of liver stage infection in this model (Figure 3.5B-D). 
dRTS,S and dR21 demonstrated overall potent protection of 81.5% and 82.6% inhibition 
respectively (Figure 3.5B-D). Beginning on day 4 post-infection, blood smears were 
taken to evaluate protection from blood stage parasitemia. All mice immunized with the 
empty vector control, pVax, succumbed into blood stage infection by day 4. Of the five 
mice immunized with dRTS,S, two mice developed blood stage parasitemia by day 5, 
and a third on day 6. Of the five mice immunized with dR21, one developed blood stage 
parasitemia at day 4, a total of three by day 5, and 4/5 mice had developed parasitemia 
by day 6 post infection. Of the mice immunized with ΔGPI, one fell ill by day 4, and a 
second by day 5, leaving 3/5 mice with sterile protection from blood stage parasitemia. 
Finally, of the mice treated with 100 ug of the MAb 311 as a positive control, one 
developed BS parasitemia by day 4, and a second developed BS parasitemia by day 8, 
leaving 3/5 mice with sterile protection from blood stage parasitemia (Figure 3.5E) and 
serves as a robust control. This is the first demonstration that genetically encoded 
dRTS,S or dR21 can drive robust protection, similar to prior reports of these 
immunogens as protein based vaccines. Furthermore, in the side by side comparison 
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ΔGPI exhibited protection which was comparable to the genetically encoded dRTS,S 
and dR21, as well as the monoclonal antibody positive control.   
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Discussion 
CSP has long been a focus in malaria vaccine research, and for good reason, as 
anti-CSP antibodies are one of the predominant correlates of protection for malaria 
infection187. CSP is composed of an N-terminal domain containing a conserved 
proteolytic cleavage cite, a central repeat region, and a c-terminal domain173. CSP 
undergoes significant conformational change during the parasite’s migration from the 
mosquito salivary gland to the mammalian liver. When first entering the bloodstream, 
CSP is in a folded conformation on the surface of the sporozoite. As the parasite 
reaches the liver, CSP undergoes proteolytic cleavage, which has been shown to be a 
critical requirement for hepatocyte invasion174. In addition it is known that antibody 
binding to sporozoites abolish their motility193 and  induces a cytotoxic effect194 that 
neutralize their infectivity. Consequently, antibodies targeting CSP have the potential to 
strongly inhibit sporozoite invasion of hepatocytes and can thus be protective against 
disease195.  
RTS,S is a recombinant protein-based vaccine comprised of a fragment of CSP 
containing a section of the repeat region, and the T cell epitopes of the c-terminus 
attached to the Hepatitis B surface antigen protein, and delivered with additional HbsAg 
to encourage the formation of virus-like-particles in yeast, which are then harvested and 
administered with an adjuvant to humans to generate a T cell and antibody response. In 
contrast, while the R21 vaccine is also a recombinant protein-based vaccine, containing 
the same NANP repeats and T cell epitopes of the C-terminus as RTS,S does, it is able 
to form particles in yeast without additional HbsAg, meaning that a higher proportion of 
antigen seen by the immune system will be Plasmodium antigen rather than Hepatitis B 
antigen. RTS,S, when formulated with adjuvant, induces antigen-specific humoral and 
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CD4 T cell cellular responses in BALB/c mice196 and in humans 197–200. R21, when 
formulated with adjuvant or delivered with a TRAP-based viral vector prime-boost, also 
demonstrated a robust humoral and cellular response69. Genetically encoded RTS,S and 
R21 surrogates were highly immunogenic and protective in a rigorous malaria challenge 
model and performed similarly to their protein counterparts69,196–199,201. However, the 
majority of the IFNy response elicited by dRTS,S and dR21 was directed against the 
HbsAg rather than against CSP. In contrast, our primary CSP candidate vaccine, ΔGPI, 
elicited a cellular response to only CSP, not to HbsAg, thus the response appears more 
focused towards the CSP antigen targeted by the vaccine.  
This study demonstrates the potential for a synDNA vaccine targeting CSP to be 
highly immunogenic and efficacious. I show that a synthetic DNA vaccine targeting the 
circumsporozoite protein of Plasmodium falciparum can induce a high-titer anti-CSP 
antibody response, as well as a robust cellular response producing IFNy in response to 
stimulation with CSP antigen. This immunogenicity elicited by the ΔGPI CSP vaccine 
resulted in protection from infection in multiple models of murine malaria, including an IV 
sporozoite challenge, and a rigorous infected mosquito bite challenge. Additionally, this 
study is the first to show that synDNA mimics of the leading CSP vaccine candidates 
RTS,S and R21 generate strong humoral and cellular responses, resulting in protection 
from infection in an infected mosquito bite challenge model. 
Nanoparticle vaccines have become a focus in recent years. Nanoparticles, 
ordered structures with dimensions in the range of 1-1000 nm, can function as both a 
delivery system, and/or immune potentiators202,203. Nanoparticles which have a 
comparable size to pathogens are taken up efficiently by APCs202. Further, the display of 
antigen in a repetitive array mimics the surface of a pathogen (i.e. as CSP densely coats 
the surface of sporozoites), and this allows for enhancement of innate immune 
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activation, improved drainage and retention in the lymph node, stronger engagement 
with B cell receptors, and consequently augmented T cell help to B cells203. Within the 
context of prophylactic malaria vaccines, nanoparticle vaccines have been shown to 
drive broader humoral responses, a balanced Th1/Th2 cytokine profile, and robust 
germinal center formulation204. Malaria protein targeting nanoparticles have also been 
shown to increase Ab titers, and increase antigen specific plasmablasts, circulating 
memory B cells, and plasma cells in the bone marrow, as well as inducing antigen 
specific circulating Tfh cells205. There is precedent for synDNA launched nanoparticle 
vaccines spontaneously self-assembling in vivo, and driving stronger humoral responses 
than monomeric DNA vaccines186.Thus I postulate that our synDNA vaccine mimics of 
the nanoparticle forming RTS,S and R21 vaccines, as well as our novel synDNA vaccine 
“ΔGPI”, all of which form high molecular weight aggreagtes which may be nanoparticles 
in vitro, may promote enhanced trafficking to lymph nodes, robust germinal center 
formation, and consequent increases in anti-CSP antibodies as compared to non-
nanoparticle forming vaccines.  
I believe this platform of in-vivo launched polyvalent nanoparticle vaccines 
targeting CSP has the potential to deliver high level protection from malaria infection, in 
a temperature stable and cost-effective manner which makes it particularly well suited to 
use in low-resource settings. 
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Materials and Methods 
Cell lines and transfection 
To probe for in vitro expression of the vaccine constructs, the Expi293F 
transfection kit (ThermoFisher) was used for all transfections. Expi293F cells were 
maintained in Expi293 Expression Medium for passages, and cells were incubated in 8% 
CO2 conditions on an orbital shaker at 37°C. Briefly, one day prior to transfection, 2x105 
Expi293F cells at 95% viability or greater were plated in Expression Medium. DNA 
plasmids were added to Opti-MEM media separately from ExpiFectamine transfection 
reagent. After a 5-minute incubation period, DNA and ExpiFectamine were complexed 
during a 20-minute incubation period. Subsequently, the DNA plasmid complex was 
added to Expi293F cells in suspension. Eighteen hours after the addition of DNA, 
Transfection Enhancers were added according to manufacturer’s instructions. After three 
to five days, cell supernatants and lysates were collected for further studies.  
Western Blot 
To detect vaccine construct expression in transfection supernatants and lysates, 
12µL of sample was run on 4-12% Bis-Tris gel (ThermoFisher) in MES buffer. Samples 
were boiled and reduced before being run. Upon completion of the gel, contents of the 
gel were transferred to a nitrocellulose membrane via the iBlot 2 Transfer system 
(ThermoFisher). Upon transfer completion, the membrane was blocked using Intercept 
Blocking Buffer (LI-COR) for one hour at room temperature. After blocking, the 
membranes were probed with the anti-CSP human MAb 311 at a 1:1000 dilution in 
blocking buffer at 4°C overnight. The following day, a fluorescently labelled anti-human 
secondary antibody was added to the membrane, formulated in Intercept Blocking 
Buffer, SDS, PBS, and Tween-20 for a one-hour incubation. Following secondary 
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incubation, the membrane was washed with PBS + 0.1%% Tween-20 four times, and 
was subsequently imaged using the LI-COR Odyssey CLx.  
Ultracentrifugation and gradient fraction collection  
In order to assess the polyvalency and structural formation of vaccine constructs, 
transfectant supernatants were collected and filtered through a 0.45micron filter to 
remove cell debris. Then an Amicon Ultra-15mL 10k filter was used to concentrate 15 
mL of sample with a 4,000x g spin for approximately 15-40 minutes. Concentrated 
protein (1g) was loaded onto a 5ml 10-50% discontinuous sucrose gradient (50 mM Tris, 
pH 8, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10-50% 
sucrose) and ultracentrifuged (39,800 rpm) for 24 hours at 4°C. Fractions (250 µL) were 
collected and stored at -20°C.  
Electron Microscopy 
Fractions were collected from the density gradient analysis, and dialysed into 
PBS overnight using Slide-A-Lyzer mini dialysis devices (ThermoFisher), before being 
concentrated via an Amicon Ultra-0.5mL 10k filter. 3 µl of each sample was applied to a 
thin carbon grid that was glow discharged for 30 seconds at 30 mAmps current using 
pelco easyglow glow discharger. 3µl of freshly made solution of 2% uranyl acetate was 
used to stain each sample twice on the grid with 1 min of incubation time. Excess stain 
and sample were removed by carefully blotting the grid at the edge with a Whatman filter 
and the grid was allowed to dry until imaged. TEM micrographs were collected using 
Tecnai T12 TEM microscope operated at 100KeV and the images were recorded at 20x 
mag on Gatan 4K CMOS camera. 
ELISA 
For binding detection of CSP in transfection supernatants as well as 
quantification of serum antibody titers, MaxiSorp 96-well plates or half-area plates 
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(ThermoFisher) were coated overnight with 1 µg/mL of recombinant CSP (courtesy of 
MVI/PATH) at 4°C. The next day, each plate was washed with Phosphate Buffered 
Saline + 0.01% Tween-20 (PBS-T) four times (4x). Plates were then blocked with 5% 
milk in PBS for two hours at RT. Upon completion of blocking, plates were washed 
again, and samples diluted in 1% newborn calf serum (NCS) in PBST were transferred 
onto the plates for a two-hour incubation at RT. Following sample incubation, plates 
were washed, and goat anti-mouse or anti-human heavy and light chain HRP conjugated 
secondary was diluted to 1:10,000 and transferred onto plates for a one-hour incubation 
at RT. After secondary incubation, plates were washed and developed using 
SIGMAFAST™ OPD (Sigma-Aldrich) for 10 minutes and then stopped with sulfuric acid. 
The Biotek Synergy 2 plate reader was used to read plates at 450 nm. Data were 
exported to Microsoft Excel and analyzed using GraphPad PRISM 8. 
Animal studies and immunizations 
BALB/c mice were purchased from the Jackson Laboratory. Animal experiments 
were conducted under protocol #201236 approved by the Wistar Institutional Animal 
Care and Use Committee (IACUC). All animals were housed in the Wistar Institute 
Animal Facility, with the exception of challenge studies, which were performed at the 
Johns Hopkins Bloomberg School of Public Health. Mice were immunized with 25µg of 
DNA in sterile water intramuscularly in the tibialis anterior (TA) muscle and subsequently 
electroporated using the CELLECTRA 3P adaptive electroporation device (Inovio 
Pharmaceuticals). Mice were immunized four times, three weeks apart for all 
experiments, including the challenge experiments. One week following each vaccination, 
blood was collected via submandibular bleed to isolate sera for future experiments. In 
addition, one week after the final immunization, mice were euthanized for splenocyte 
collection for subsequent assays.  
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Sample processing and ELISpot 
Following euthanasia, spleens were harvested and temporarily stored in R10, 
consisting of 10% FBS and 1% penicillin-streptomycin in RPMI 1640 (Invitrogen). Using 
the Stomacher 80 tissue stomacher, spleens were homogenized for one minute before 
filtering through a 40µm strainer. The cell mixture was centrifuged for 10 min at 1200 
rpm and subsequently resuspended in ACK lysis buffer (Gibco) for a 5 minute period. 
Cells were washed with PBS prior to centrifugation and resuspension in 20mL R10 
media for counting on a COUNTESS II (Invitrogen). 
To assess antigen specific interferon gamma (IFNγ) production, mouse IFNγ 
ELISpot PLUS (Mabtech) plates were used according to the protocol provided by the 
manufacturer. Briefly, plates were washed using sterile PBS followed by blocking with 
200µL per well of R10. Plates were seeded with 200,000 cells in 100µL R10 in triplicate. 
Cells were stimulated with peptide pools of 15mers overlapping by 11 amino acids 
spanning the entire vaccine antigen at a final concentration of 5 μg/mL per peptide. R10 
and Concanavalin A were used as negative and positive controls, respectively. After an 
18-hour incubation in 5% CO2 conditions at 37°C, plates were developed according to
the protocol provided by the manufacturer. After developing, the CTL ImmunoSpot S6 
Universal Analyzer (Cellular Technology Limited) was used to scan and count plates. 
Data analysis was performed using GraphPad PRISM 8.  
IV sporozoite challenge 
Challenge study was performed at Johns Hopkins under IACUC #MO16H35. 
Each mouse was immunized via intramuscular injection followed by electroporation on 
weeks 0, 3, 6 and 9. On week 11 of the experiment, mice were challenged with 
Plasmodium berghei (Pb) transgenic parasites that express the full-length Plasmodium 
falciparum circumsporozoite protein (PfCSP), as well as luciferase to report liver parasite 
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load as described192. This parasite is denoted from this point on as PbPfLuc. Briefly, the 
311-100 μg cohort was injected with 100 μg of human mAb 311 16 hours prior to
challenge, and age-matched all other mice; this cohort served as a control for protection. 
42 hours after intravenous injection of 250 sporozoites, mice were intraperitoneally 
injected with 100 μl of D-luciferin (30 mg/mL), anesthetized and liver luminescence was 
measured with the Perkin Elmer IVIS Spectrum Imaging System to assay liver loads. 
Mann Whitney tests were used to compare luminescence between immunized groups 
and the naïve control. 
Infectious mosquito bite challenge  
Challenge study was performed at Johns Hopkins under IACUC #MO16H35. 
Each mouse was immunized via intramuscular injection followed by electroporation on 
weeks 0, 3, 6 and 9. Serum was isolated from each mouse via retro orbital bleeding 3 
days prior to challenge. The 311-100 μg cohort was injected with 100 μg of human mAb 
311 16 hours prior to challenge, and age-matched all other mice; this cohort served as a 
control for protection. On week 12 of the experiment, mice were challenged with 
PbPfLuc via infectious mosquito bite. A cage of Anopheles stephensi mosquitoes, 20 
days after blood feeding on PbPfLuc infected mice was determined to be 90% infected 
with PbPfLuc. Based on this calculation, it was determined that 5 mosquitoes were 
needed to challenge mice with infected mosquito bites, as described192. Briefly, mice 
were anesthetized with 2% Avertin prior to challenge. Mosquitoes were allowed to feed 
on mice for ~10 minutes. After feeding, the number of mosquitoes positive for a blood 
meal was determined. 42 hours after mosquito bite challenge, liver parasite load was 
measured using the Perkin Elmer IVIS Spectrum Imaging System. Mice were injected 
with 100µl of D-Luciferin (30mg/mL), anesthetized with isoflurane and imaged with the 
IVIS Spectrum to measure bioluminescence expressed by the transgenic parasites. 
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Mann Whitney tests were used to compare luminescence between immunized groups 
and the naïve control. Blood smears were taken beginning on day 4 post-infection to 
evaluate parasitemia. A positive result was considered an endpoint. Mice were 






Figure 3.1 DNA vaccine construct design and in vitro expression. (A) Schematic diagram of 
Plasmodium falciparum (Pf) gene inserts used to generate the codon-optimized DNA vaccine 
constructs. The schematic details leader sequence (IgE) and gene insert. *This does not 
represent the true structure of CSP, and is merely a graphic (B) in-vitro expression of vaccine 
constructs in 293T cells via western blot, anti-CSP monoclonal Ab MAb 311 used as probe. 









Figure 3.2: synDNA CSP vaccine constructs elicit a robust immune response and are 
protective against IV sporozoite Pf challenge 
(A) Experiment layout. Mice were immunized four times, three weeks apart, and challenged
with 250 sporozoites IV three weeks after the last immunization. Sera was collected prior to
challenge for Ab analysis. Liver parasite burden was measured by IVIS. In a separate
experiment mice received the same treatment, and splenocytes were harvested for immune
cell analysis as in panel D. (B-C) ELISA’s of pooled sera for each cohort. Panel B tested sera
against recombinant CSP, while panel C tested sera against the NANP peptide. Sera was
initially diluted 1:200, and 3-fold serial dilutions were made afterwards. Monoclonal
antibody 2A10 was used as a positive control. (D) The Pf CSP antigen-specific cellular
immune response induced by the indicated DNA vaccine measured by IFNγ ELISPOT. Cells
were stimulated for 18 hr with peptide pools encompassing the entire protein. (E) Graphical
representation of luminescence data. Bar graph of mean luminescence for each group, and
results of Mann Whitney tests comparing groups to Naive Infected. Both AB311 and dGPI
demonstrate statistically significant differences compared to Naive Infected (**:P < 0.05). (F)
Inhibition of liver infection as expressed as a function of relative infection compared to naive
mice. Mice immunized with dGPI have the highest inhibition of liver infection (64.17%),
while 311 treatment demonstrates an 80% inhibition of liver stage infection. (G)







Figure 3.3: The development of benchmark CSP control vaccines. (A) Schematic diagram of 
gene inserts used to generate the DNA vaccine constructs. The schematic details leader 
sequence (IgE) and gene insert, as well as ratio of delivery. (B) western blot of construct 
expression, supernatants from transfected 293T cells were probed with the MAb 311 (anti-
CSP) (C) Discontinuous sucrose gradient fractions probed for CSP. The high molecular weight 
fractions denoted in red boxes were combined and imagined by negative staining electron 
microscopy as shown in (D). (D) Particle formation of vaccines in vitro. Examples of particles 
are encircled (not exhaustive, i.e. not all particles are circled). 
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Figure 3.4: synDNA CSP constructs elicit a robust response. Mice were immunized four 
times, three weeks apart. Sera and splenocytes were collected three weeks after the last 
immunization for immune analysis. (A) ELISAs to assess rCSP binding by Ab elicited after final 
vaccination. (B) ELISAs to assess HBsAg binding by Ab elicited after final vaccination (C) The 
Pf CSP antigen-specific cellular immune response induced by the indicated DNA vaccine 
measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools encompassing 
the entire protein. (D) The HBsAg specific cellular immune response induced by the indicated 
DNA vaccine measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools 
encompassing the entire protein.  
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Figure 3.5: synDNA CSP constructs are protective in challenge. (A) Experimental layout: 
Mice were immunized four times, three weeks apart, and challenged three weeks after the 
last immunization by infected mosquito bite. Liver parasite burden was assessed by IVIS. 
Blood parasite burden was assessed by daily blood smears. (B) Graphical representation of 
luminescence data. Bars indicate the mean and standard deviations. Bar graph of means and 
results of Mann Whitney tests comparing groups to Naive Infected. (C) Inhibition of liver 
infection as expressed as a function of relative infection compared to naive mice. (D) 
representative IVIS images from each group (E) %blood stage parasite free mice, as assessed 
by blood smears each day post challenge. 
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CHAPTER 4: Discussion and Conclusions
4.1 Strategic interruption of the Plasmodium life cycle 
As discussed in chapter 1, understanding the Plasmodium lifecycle and its points 
of weakness is crucial to developing effective interventions. The Plasmodium lifecycle 
has several “bottleneck” steps which make enticing vaccine targets. One of these so-
called bottlenecks is the invasion of hepatocytes by sporozoites. Although many 
sporozoites are injected in the saliva of the mosquito vector, the majority of them die in 
the dermis and never migrate to the liver. While the number of sporozoites which leave 
the dermis and migrate to the liver is small, if even one sporozoite manages to evade 
immune detection and removal, schizogony in the liver will result in tens of thousands of 
merozoites to cause the symptomatic blood infection. If the goal of a prophylactic 
malaria vaccine is the same as most prophylactic vaccines- that is, to prevent 
symptomatic disease, then it is clear that our focus should be on a pre-erythrocytic 
vaccine. Two strategies of pre-erythrocytic vaccines are (1) to prevent the sporozoites 
from successfully invading hepatocytes and (2) to kill infected hepatocytes before 
merozoite development is complete (Figure 4.1).  
In chapter 2 I focused on the second strategy, cell mediated immunity targeting 
the liver stage of infection. The studies in this chapter built off of previous work in the 
field of malaria vaccinology which highlighted the importance of both CD4+ and CD8+ T 
cells in anti-malaria immunity, namely studies by Steven Hoffman’s206–208 and Stephan 
Kappe’s66,84,153 groups on irradiated and genetically attenuated sporozoites, respectively. 
I showed that a synDNA vaccine targeting liver stage Plasmodium antigens can drive an 
antigen specific liver localized T cell population. I demonstrated through T cell assays 
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including ELISpots and Flow Cytometry that synDNA vaccination with EXP1, PFN, 
EXP2, ICP, UIS3, and TMP21, in combination or alone, elicits a robust T cell response, 
as well as the production of antibodies against these peptides. This T cell response was 
consequential, and resulted in 70-88% protection from blood-stage disease in an IV 
sporozoite challenge model of murine malaria infection. The use of the molecular 
adjuvant pIL-33 increased the immune response to vaccine and results in 100% 
protection from blood stage disease after sporozoite challenge. I hypothesize that this 
increase in protective efficacy in the adjuvanted groups is related to the increase in in 
antigen responsive liver associated T cells, as well as their polyfunctionality as 
demonstrated by enhanced cytokine poly-positivity in adjuvanted groups, though this 
hypothesis should be investigated further to elucidate mechanism in more detail. 
Altogether, the data suggest cell-mediated immunity against this obligate intracellular 
stage of the pathogen should be considered when designing anti-malarial vaccines, and 
support the continued examination of liver stage antigens as components of a 
prophylactic vaccine. Additional focus on LS antigens as a component of a malaria 
vaccine is warranted, potentially in combination with sporozoite antigens such as CSP. 
In chapter 3 I focused on the first strategy of pre-erythrocytic vaccines, 
prevention of sporozoite invasion and establishment of liver infection. This work was 
largely inspired by the RTS,S vaccine studies which implicated antibodies against CSP 
as a key correlate of protection180,197,200,201. In these studies, I showed that a synDNA 
vaccine targeting the circumsporozoite protein of Plasmodium falciparum can induce a 
high-titer anti-CSP antibody response, as well as a robust cellular response producing 
IFNy in response to stimulation with CSP antigen. This immunogenicity elicited by the 
ΔGPI CSP vaccine resulted in protection from infection in multiple models of murine 
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malaria, including an IV sporozoite challenge, and a rigorous infected mosquito bite 
challenge. Additionally, this study is the first to show that synDNA mimics of the leading 
CSP vaccine candidates RTS,S and R21 generate strong humoral and cellular 
responses, resulting in protection from infection in an infected mosquito bite challenge 
model. However, the majority of the IFNy response elicited by dRTS,S and dR21 was 
directed against the HbsAg rather than against CSP. In contrast, our primary CSP 
candidate vaccine, ΔGPI, elicited a cellular response to only CSP, not to HbsAg, thus 
the response appears more focused towards the CSP antigen targeted by the vaccine. It 
would be interesting to compare the original protein and adjuvant formulations of RTS,S 
and R21 against the synDNA mimics we developed, as well as against our own novel 
anti-CSP vaccine ΔGPI. It is possible that the synDNA platform would offer a novel and 
potentially more immunogenic method of delivery for vaccine antigens such as CSP. I 
believe this platform of DNA encoded, in-vivo launched vaccines targeting CSP has the 
potential to deliver high level protection from malaria infection, in a temperature stable 
and cost-effective manner which makes it particularly well suited to use in low-resource 
settings. 
In both of these series of studies, I demonstrated the efficacy of targeting the pre-
erythrocytic stages of infection for prevention of disease. I found that targeting either of 
the pre-erythrocytic stages, sporozoites or liver stage, elicited robust immunity to malaria 
infection in a murine challenge model. I consequently hypothesize that a multi-valent 
vaccine which targets both pre-erythrocytic stages of infection may exhibit synergistic 
effects.  
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4.2 The next generation of malaria vaccines: emphasis on multivalency and 
advanced platforms   
Prior vaccine studies suggest that a mono-antigen vaccine will be of limited use 
in preventing a disease with such a varied antigenicity and multiple strains. Mono-
antigenic vaccines, notably RTS,S, have had limited success. The fact that the most 
robust protection is elicited by attenuated sporozoites is indicative of the need for a 
vaccine which targets many antigens and potentially multiple lifecycle stages. The next 
generation of malaria vaccines will need to be cognizant of this. The field of malaria 
vaccine development has been plagued by several challenges. The first is the 
questionable usefulness of the murine models which are widely used209. Even within a 
single species of Plasmodium, there is wide antigenic variability between strains, and the 
variability between species is even higher. Because of this, many groups have begun 
testing their novel vaccines in controlled human malaria infections (CHMI), in which 
naïve western volunteers are vaccinated and subsequently challenged with a single 
strain of Plasmodium falciparum210. However, even this model of malaria infection has 
significant constraints, as vaccines which perform remarkably well in CHMI trials 
(RTS,S211, irradiated sporozoites212) struggled when deployed in areas of endemic 
infection. One potential cause of this dissonance is the interference of natural immunity 
with vaccine elicited immunity. It has been shown that non neutralizing antibodies 
against the sporozoite can abrogate protection from neutralizing antibodies, which may 
be a mechanism through which Plasmodium evades vaccine immunity213. Unfortunately, 
unlike immunity to many viral infections, natural immunity to malaria infection has not 
been a fount of wisdom to inform vaccine design. As discussed in chapter 1.3, natural 
immunity to malaria is strain-specific, built up slowly over time, and wanes quickly. We 
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must continue to toil to understand natural immunity to malaria, and if we cannot mimic it 
to design effective vaccines, we must understand how to work with it rather than against 
it, OR how to avoid the potential inhibitory effects of natural immunity on vaccine elicited 
immunity.  
The next generation of malaria vaccines must be able to elicit durable, cross-
strain protection. Some of the answer to this dilemma lies in the choice of antigen or 
antigens included in the vaccine, and some lies in the choice of vaccine platform. I argue 
that the ideal malaria vaccine will include antigens from multiple life cycle stages, both 
pre-erythrocytic and erythrocytic. Including pre-erythrocytic antigens will aim to prevent 
the infection from reaching the symptomatic blood stage, and including erythrocytic 
antigens will aim to mitigate the symptoms in the case of breakthrough infection. The 
inclusion of a transmission blocking antigen, as discussed in chapter 1.4, may also be a 
valuable addition to the malaria elimination arsenal. In addition to antigen selection, 
vaccine platform will also be of importance. As covered in chapter 1.5, the 1st and 2nd 
generation vaccine platforms, while formidable and hugely important in eradicating, 
eliminating, or greatly decreasing many pathogens of importance for human and animal 
health, have historically struggled to elicited the CD8+ T cell mediated immunity needed 
to control pathogens with an obligate intracellular stage of infection. Novel vaccine 
platforms, such as nucleic acid vaccines and nanoparticle vaccines, will be able to 
address this gap in vaccine elicited immunity in future vaccination endeavors.  
4.3 Concluding remarks 
Although I strongly believe in the power of vaccines to control infectious 
diseases, it is unlikely that any one prophylactic malaria vaccine will be a silver bullet. 
Rather, a prophylactic malaria vaccine like RTS,S or one of the nucleic acid vaccine 
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strategies described above are an important part of the global health community’s 
arsenal in combatting one of humanity’s most ancient foes. Other aspects of this arsenal 
include novel therapeutics, continued vigilance against drug resistant parasites and 
pesticide resistant mosquitoes, and the continued use of bed nets and other such 
avoidance techniques. The WHO Global Technical Strategy for Malaria 2016-2030 
established the goals of 1) reducing malaria case incidence by 90% by 2030, 2) reducing 
malaria mortality by at least 90%, and 3) eliminating malaria in at least 35 countries27. 
Through a coordinated, interdisciplinary effort between immunologists, parasitologists, 
vaccinologists, epidemiologists and others we can look to a future where these goals 
have been realized. Eventually, though perhaps not by 2030, I believe the combined 
efforts of generations of scientists, doctors, and public health officials will culminate in a 
world free of malaria.  
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Figure 4.1: Strategic interruption of the Plasmodium life cycle. Life cycle stages to be 
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